###begin article-title 0
Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity
###end article-title 0
###begin p 1
These authors contributed equally to this work
###end p 1
###begin p 2
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits distribution, and reproduction in any medium, provided the original author and source are credited. This license does not permit commercial exploitation or the creation of derivative works without specific permission.
###end p 2
###begin p 3
###xml 132 136 <span type="species:ncbi:10090">mice</span>
It is widely accepted that reactive oxygen species (ROS) promote tumorigenesis. However, the exact mechanisms are still unclear. As mice lacking the peroxidase peroxiredoxin1 (Prdx1) produce more cellular ROS and die prematurely of cancer, they offer an ideal model system to study ROS-induced tumorigenesis. Prdx1 ablation increased the susceptibility to Ras-induced breast cancer. We, therefore, investigated the role of Prdx1 in regulating oncogenic Ras effector pathways. We found Akt hyperactive in fibroblasts and mammary epithelial cells lacking Prdx1. Investigating the nature of such elevated Akt activation established a novel role for Prdx1 as a safeguard for the lipid phosphatase activity of PTEN, which is essential for its tumour suppressive function. We found binding of the peroxidase Prdx1 to PTEN essential for protecting PTEN from oxidation-induced inactivation. Along those lines, Prdx1 tumour suppression of Ras- or ErbB-2-induced transformation was mediated mainly via PTEN.
###end p 3
###begin title 4
Introduction
###end title 4
###begin p 5
###xml 302 303 302 303 <sub>2</sub>
###xml 304 305 304 305 <sub>2</sub>
###xml 354 364 354 364 <xref ref-type="bibr" rid="b32">Rhee, 2006</xref>
###xml 459 464 459 464 <italic>et al</italic>
###xml 454 471 454 471 <xref ref-type="bibr" rid="b1">Chae <italic>et al</italic>, 1994a</xref>
###xml 1080 1102 1080 1102 <xref ref-type="bibr" rid="b25">Neumann and Fang, 2007</xref>
###xml 1284 1285 1284 1285 <sub>2</sub>
###xml 1286 1287 1286 1287 <sub>2</sub>
###xml 1370 1375 1370 1375 <italic>et al</italic>
###xml 1362 1381 1362 1381 <xref ref-type="bibr" rid="b26">Neumann <italic>et al</italic>, 2003</xref>
###xml 1528 1533 1528 1533 <italic>et al</italic>
###xml 1522 1539 1522 1539 <xref ref-type="bibr" rid="b5">Egler <italic>et al</italic>, 2005</xref>
###xml 1145 1149 <span type="species:ncbi:10090">mice</span>
###xml 1227 1231 <span type="species:ncbi:10090">mice</span>
Peroxiredoxins (Prdxs) are a superfamily of small non-seleno peroxidases (22-27 kDa) currently known to possess six mammalian isoforms. Although their individual roles in cellular redox regulation and antioxidant protection are quite distinct, they all catalyse peroxide reduction to balance cellular H2O2 levels essential for signalling and metabolism (Rhee, 2006). Prdxs I-IV share the common CxxC motif and use thioredoxin (Trx) as an electron donor (Chae et al, 1994a). On reaction with peroxides, the Prdxs' 'peroxidatic' cysteine (Cys51 in Prdx1) is oxidized into a sulfenic acid intermediate, which then forms a disulfide bond with the 'resolving' cysteine (Cys172 in Prdx1) from the other homodimer's subunit. Catalytic reduction of peroxides results in different oxidation states of the catalytic cysteine. Lower oxidation states (sulfenic acid) are reduced back to thiol by the Trx system. Higher oxidation states such as sulfinic acid can be reduced back to thiol by sulfiredoxin, whereas the oxidation to sulfonic acid is irreversible and results in Prdx degradation (Neumann and Fang, 2007). Loss of Prdx1 shortens the life span of mice due to the development of hemolytic anemia and cancer. Analysis of cells and mice lacking Prdx1 suggested that it not only regulated H2O2 levels, but also that it possessed the properties of a tumour suppressor (Neumann et al, 2003), which was further supported by the finding that Prdx1 interacts with c-Myc thereby selectively inhibiting c-Myc transcriptional activity (Egler et al, 2005).
###end p 5
###begin p 6
###xml 142 143 142 143 <italic>K</italic>
###xml 143 144 143 144 <sub>a</sub>
###xml 164 165 164 165 <italic>K</italic>
###xml 165 166 165 166 <sub>a</sub>
###xml 227 248 227 248 <xref ref-type="bibr" rid="b46">Zhang and Dixon, 1993</xref>
###xml 257 262 257 262 <italic>et al</italic>
###xml 250 268 250 268 <xref ref-type="bibr" rid="b29">Peters <italic>et al</italic>, 1998</xref>
###xml 609 610 609 610 <sub>2</sub>
###xml 611 612 611 612 <sub>2</sub>
###xml 759 764 759 764 <italic>et al</italic>
###xml 752 770 752 770 <xref ref-type="bibr" rid="b17">Leslie <italic>et al</italic>, 2003</xref>
###xml 777 782 777 782 <italic>et al</italic>
###xml 772 788 772 788 <xref ref-type="bibr" rid="b14">Kwon <italic>et al</italic>, 2004</xref>
###xml 1114 1119 1114 1119 <italic>et al</italic>
###xml 1110 1125 1110 1125 <xref ref-type="bibr" rid="b16">Lee <italic>et al</italic>, 2002</xref>
###xml 1132 1137 1132 1137 <italic>et al</italic>
###xml 1127 1143 1127 1143 <xref ref-type="bibr" rid="b14">Kwon <italic>et al</italic>, 2004</xref>
###xml 1304 1309 1304 1309 <italic>et al</italic>
###xml 1297 1315 1297 1315 <xref ref-type="bibr" rid="b17">Leslie <italic>et al</italic>, 2003</xref>
###xml 803 808 <span type="species:ncbi:9606">human</span>
Peroxides are known to modify protein tyrosine phosphatases (PTPs) by oxidation. PTP catalytic property depends on a thiolate anion of a low pKa cysteine residue (pKa 4.7-5.4) located in the conserved motif of its active site (Zhang and Dixon, 1993; Peters et al, 1998). This highly nucleophilic group makes the initial attack on the phosphate group of the substrate, but renders the PTP extremely susceptible to oxidation resulting in its inactivation. The PTP and tumour suppressor PTEN exhibits phosphatase activity towards phosphoinositides and tyrosine phosphates and is known to be inactivated through H2O2-mediated oxidation or through growth factor signalling, including epithelial growth factor (EGF) or platelet-derived growth factor (PDGF) (Leslie et al, 2003; Kwon et al, 2004). Analysis of human recombinant PTEN revealed that two of the five cysteines in its N-terminal phosphatase domain (PTD) (Cys71 and Cys124) form a disulfide bond after oxidation, which resulted in the transient inhibition of its phosphatase activity and allowed oxidized PTEN to migrate faster on a non-reducing SDS-PAGE (Lee et al, 2002; Kwon et al, 2004). In stimulated macrophages, PTEN oxidation led to the temporary inhibition of its phosphatase activity and in the phosphorylation of Akt on Serine 473 (Leslie et al, 2003).
###end p 6
###begin p 7
###xml 53 77 53 77 <xref ref-type="bibr" rid="b11">Keniry and Parsons, 2008</xref>
###xml 193 198 193 198 <italic>et al</italic>
###xml 183 204 183 204 <xref ref-type="bibr" rid="b38">Stambolic <italic>et al</italic>, 1998</xref>
###xml 411 419 411 419 <italic>in vitro</italic>
###xml 424 431 424 431 <italic>in vivo</italic>
###xml 439 444 439 444 <italic>et al</italic>
###xml 433 450 433 450 <xref ref-type="bibr" rid="b35">Sheng <italic>et al</italic>, 2001</xref>
###xml 463 468 463 468 <italic>et al</italic>
###xml 452 474 452 474 <xref ref-type="bibr" rid="b10">Hutchinson <italic>et al</italic>, 2004</xref>
###xml 476 497 476 497 <xref ref-type="bibr" rid="b20">Lim and Counter, 2005</xref>
###xml 608 616 608 616 <italic>in vitro</italic>
###xml 620 627 620 627 <italic>in vivo</italic>
###xml 629 654 629 654 <xref ref-type="bibr" rid="b39">Tolkacheva and Chan, 2000</xref>
###xml 661 666 661 666 <italic>et al</italic>
###xml 656 672 656 672 <xref ref-type="bibr" rid="b13">Koul <italic>et al</italic>, 2002</xref>
###xml 38 43 <span type="species:ncbi:9606">human</span>
PTEN deficiency is a hallmark of many human tumours (Keniry and Parsons, 2008) and is accompanied by enhanced cell proliferation, decreased cell apoptosis and increased Akt activity (Stambolic et al, 1998). Akt is regulated by PI3K and PTEN, thus playing a central role particularly in Ras- and ErbB-2-induced transformation. Akt activity has been proven crucial for the initiation of this transformation, both in vitro and in vivo (Sheng et al, 2001; Hutchinson et al, 2004; Lim and Counter, 2005) and phosphatase inactive PTEN (PTEN Cys124Ser) is incapable of suppressing Ras-induced transformation either in vitro or in vivo (Tolkacheva and Chan, 2000; Koul et al, 2002).
###end p 7
###begin p 8
###xml 342 343 342 343 <sub>2</sub>
###xml 344 345 344 345 <sub>2</sub>
Although it is known that PTEN activity is negatively regulated through oxidation, the existence of a protective mechanism inhibiting such inactivation has not been proposed. On the basis of our findings, we propose here that Prdx1 promotes PTEN tumour suppressive function by binding PTEN and protecting its lipid phosphatase activity from H2O2-induced inactivation. This way, Prdx1 controls excessive cellular Akt activity and reduces the susceptibility to H-Ras and ErbB-2-induced transformation.
###end p 8
###begin title 9
Results
###end title 9
###begin title 10
Prdx1 inhibits Ras-induced transformation through its peroxidase activity
###end title 10
###begin p 11
###xml 98 99 98 99 <sub>2</sub>
###xml 100 101 100 101 <sub>2</sub>
###xml 153 154 153 154 <sub>2</sub>
###xml 155 156 155 156 <sub>2</sub>
###xml 175 186 175 186 <sup>&#8722;/&#8722;;Prdx1WT</sup>
###xml 219 222 219 222 <sup>&#8722;/&#8722;</sup>
###xml 274 291 274 291 <sup>&#8722;/&#8722;;Prdx1C51/172S</sup>
###xml 336 337 336 337 <sub>2</sub>
###xml 338 339 338 339 <sub>2</sub>
###xml 349 373 349 373 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure S1A</xref>
###xml 412 413 412 413 <sub>2</sub>
###xml 414 415 414 415 <sub>2</sub>
###xml 455 466 455 466 <sup>&#8722;/&#8722;;Prdx1WT</sup>
###xml 481 482 481 482 <sub>2</sub>
###xml 483 484 483 484 <sub>2</sub>
###xml 515 518 515 518 <sup>&#8722;/&#8722;</sup>
###xml 537 551 537 551 <sup>&#8722;/&#8722;;Cys51/172S</sup>
###xml 566 567 566 567 <sub>2</sub>
###xml 568 569 568 569 <sub>2</sub>
###xml 602 605 602 605 <sup>&#8722;/&#8722;</sup>
###xml 611 620 611 620 <xref ref-type="fig" rid="f1">Figure 1A</xref>
###xml 731 733 731 733 <sup>WT</sup>
###xml 788 789 788 789 <sub>2</sub>
###xml 790 791 790 791 <sub>2</sub>
###xml 823 832 823 832 <xref ref-type="fig" rid="f1">Figure 1A</xref>
###xml 861 871 861 871 <sup>Cys51/172S</sup>
###xml 945 950 945 950 <italic>et al</italic>
###xml 940 957 940 957 <xref ref-type="bibr" rid="b2">Chae <italic>et al</italic>, 1994b</xref>
###xml 1060 1061 1060 1061 <sub>2</sub>
###xml 1062 1063 1062 1063 <sub>2</sub>
###xml 1077 1088 1077 1088 <sup>&#8722;/&#8722;;Prdx1WT</sup>
###xml 1188 1191 1188 1191 <sup>&#8722;/&#8722;</sup>
###xml 1239 1242 1239 1242 <sup>V12</sup>
###xml 1305 1317 1305 1317 <sup>+/+;H&#8722;RasV12</sup>
###xml 1323 1332 1323 1332 <xref ref-type="fig" rid="f1">Figure 1B</xref>
###xml 1376 1378 1376 1378 <sup>WT</sup>
###xml 1419 1431 1419 1431 <sup>&#8722;/&#8722;;H&#8722;RasV12</sup>
###xml 1455 1467 1455 1467 <sup>+/+;H&#8722;RasV12</sup>
###xml 1508 1516 1508 1516 <sup>C51/172S</sup>
###xml 1561 1573 1561 1573 <sup>&#8722;/&#8722;;H&#8722;RasV12</sup>
###xml 1587 1599 1587 1599 <sup>+/+;H&#8722;RasV12</sup>
###xml 1680 1683 1680 1683 <sup>&#8722;/&#8722;</sup>
###xml 1736 1739 1736 1739 <sup>+/+</sup>
###xml 1745 1754 1745 1754 <xref ref-type="fig" rid="f1">Figure 1B</xref>
###xml 1775 1787 1775 1787 <sup>&#8722;/&#8722;;H&#8722;RasV12</sup>
###xml 1834 1846 1834 1846 <sup>+/+;H&#8722;RasV12</sup>
###xml 1879 1881 1879 1881 <sup>WT</sup>
###xml 1890 1902 1890 1902 <sup>&#8722;/&#8722;;H&#8722;RasV12</sup>
###xml 1974 1982 1974 1982 <sup>C51/172S</sup>
###xml 2044 2056 2044 2056 <sup>&#8722;/&#8722;;H&#8722;RasV12</sup>
###xml 2070 2082 2070 2082 <sup>+/+;H&#8722;RasV12</sup>
###xml 2088 2112 2088 2112 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure S1B</xref>
###xml 2165 2168 2165 2168 <sup>V12</sup>
###xml 2203 2223 2203 2223 <sup>&#8722;/&#8722;;Prdx1WT;H&#8722;RasV12</sup>
###xml 2238 2239 2238 2239 <sub>2</sub>
###xml 2240 2241 2240 2241 <sub>2</sub>
###xml 2273 2285 2273 2285 <sup>&#8722;/&#8722;;H&#8722;RasV12</sup>
###xml 2335 2340 2335 2340 <sup>&#8722;/&#8722;EV</sup>
###xml 2364 2385 2364 2385 <sup>&#8722;/&#8722;;C51/172S;H&#8722;RasV12</sup>
###xml 2424 2425 2424 2425 <sub>2</sub>
###xml 2426 2427 2426 2427 <sub>2</sub>
###xml 2455 2475 2455 2475 <sup>&#8722;/&#8722;;Prdx1WT;H&#8722;RasV12</sup>
###xml 2481 2490 2481 2490 <xref ref-type="fig" rid="f1">Figure 1C</xref>
We tested first Prdx1 peroxidase activity under physiological conditions and measured endogenous H2O2 release in growing cells over time. Extracellular H2O2 buildup from Prdx1-/-;Prdx1WTMEFs was less compared with Prdx1-/-MEFs during the 240 min measured. In contrast, Prdx1-/-;Prdx1C51/172SMEFs resulted in an excess of extracellular H2O2 buildup (Supplementary Figure S1A). Rates calculated for extracellular H2O2 buildup (pmol/min) confirmed that Prdx1-/-;Prdx1WTMEFs released H2O2 at a 30% lower rate than Prdx1-/-MEFs, whereas Prdx1-/-;Cys51/172SMEFs released H2O2-release 1.5-fold more than Prdx1-/-MEFs (Figure 1A, left panel). Western blotting analysis further confirmed that Prdx1 was functioning as a peroxidase, as Prdx1WT protein formed mostly DTT-reducible (data not shown) H2O2-scavenging dimeric structures (Figure 1A, right panel), whereas Prdx1Cys51/172S did not, as dimer formation depends on Cys51 and Cys172 disulfides (Chae et al, 1994b). The remaining Prdx1 monomers were not over-oxidized and therefore active (unlike Prdx1 monomers in H2O2-treated Prdx1-/-;Prdx1WTMEFs). Prdx1 peroxidase activity was required to suppress H-Ras-induced tumour suppression, as Prdx1-/-MEFs transduced with retrovirus expressing H-RasV12 formed two-fold more colonies in soft agar compared with Prdx1+/+;H-RasV12MEFs (Figure 1B, left panel). Expression of exogenous Prdx1WT reduced colony formation by 50% in Prdx1-/-;H-RasV12MEFs and by 20% in Prdx1+/+;H-RasV12MEFs, whereas exogenously expressed Prdx1C51/172S modestly increased colony formation in Prdx1-/-;H-RasV12MEFs and Prdx1+/+;H-RasV12MEFs. Western blot analysis ensured that re-expression of Prdx1 proteins in Prdx1-/-MEFs did not exceed those Prdx1 levels found in Prdx1+/+MEFs (Figure 1B, right panel). Prdx1-/-;H-RasV12MEFs appeared also more spindle-like than Prdx1+/+;H-RasV12MEFs, whereas expression of Prdx1WT in Prdx1-/-;H-RasV12MEFs reversed the spindle-like morphology. Expression of exogenous Prdx1C51/172S, however, promoted spindle-like cell morphology in both Prdx1-/-;H-RasV12MEFs and Prdx1+/+;H-RasV12MEFs (Supplementary Figure S1B). Analysis of the Prdx1 peroxidase activity in H-RasV12-transformed MEFs showed that Prdx1-/-;Prdx1WT;H-RasV12MEFs released H2O2 at a 26% lesser rate than Prdx1-/-;H-RasV12MEFs, which was comparable to the rate found Prdx1-/-EVMEFs. In contrast, Prdx1-/-;C51/172S;H-RasV12MEFs had a 1.5-fold increased rate of H2O2 release compared with Prdx1-/-;Prdx1WT;H-RasV12MEFs (Figure 1C).
###end p 11
###begin title 12
Loss of Prdx1 promotes PTEN oxidation and Akt activation
###end title 12
###begin p 13
###xml 149 154 149 154 <italic>et al</italic>
###xml 146 160 146 160 <xref ref-type="bibr" rid="b19">Li <italic>et al</italic>, 2004</xref>
###xml 162 183 162 183 <xref ref-type="bibr" rid="b20">Lim and Counter, 2005</xref>
###xml 210 211 210 211 <sub>2</sub>
###xml 212 213 212 213 <sub>2</sub>
###xml 298 304 297 303 <sup>Ser473</sup>
###xml 322 328 321 327 <sup>Thr308</sup>
###xml 356 359 355 358 <sup>&#8722;/&#8722;</sup>
###xml 383 386 382 385 <sup>+/+</sup>
###xml 392 401 391 400 <xref ref-type="fig" rid="f2">Figure 2A</xref>
###xml 487 490 486 489 <sup>&#8722;/&#8722;</sup>
###xml 512 515 511 514 <sup>+/+</sup>
###xml 560 575 559 574 <xref ref-type="fig" rid="f2">Figure 2B and C</xref>
###xml 620 626 619 625 <sup>Ser473</sup>
###xml 670 673 669 672 <sup>&#8722;/&#8722;</sup>
###xml 698 701 697 700 <sup>+/+</sup>
###xml 745 746 744 745 <sub>2</sub>
###xml 747 748 746 747 <sub>2</sub>
###xml 750 780 749 779 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure S2A and B</xref>
###xml 823 824 822 823 <sub>2</sub>
###xml 825 826 824 825 <sub>2</sub>
###xml 916 922 915 921 <sup>Ser473</sup>
###xml 931 937 930 936 <sup>Thr308</sup>
###xml 939 948 938 947 <xref ref-type="fig" rid="f2">Figure 2D</xref>
###xml 981 984 980 983 <sup>&#8722;/&#8722;</sup>
###xml 1013 1016 1012 1015 <sup>+/+</sup>
###xml 1022 1031 1021 1030 <xref ref-type="fig" rid="f2">Figure 2E</xref>
###xml 1085 1088 1084 1087 <sup>&#8722;/&#8722;</sup>
###xml 1115 1118 1114 1117 <sup>+/+</sup>
###xml 1134 1149 1133 1148 <xref ref-type="fig" rid="f2">Figure 2E and F</xref>
###xml 1166 1172 1165 1171 <sup>Ser473</sup>
###xml 1219 1222 1218 1221 <sup>&#8722;/&#8722;</sup>
###xml 1246 1249 1245 1248 <sup>+/+</sup>
###xml 1293 1294 1292 1293 <sub>2</sub>
###xml 1295 1296 1294 1295 <sub>2</sub>
###xml 1306 1332 1305 1331 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure S2A&#8211;D</xref>
###xml 1395 1396 1394 1395 <sub>2</sub>
###xml 1397 1398 1396 1397 <sub>2</sub>
###xml 1449 1452 1448 1451 <sup>&#8722;/&#8722;</sup>
###xml 1475 1478 1474 1477 <sup>+/+</sup>
###xml 1484 1493 1483 1492 <xref ref-type="fig" rid="f2">Figure 2G</xref>
We investigated now whether Prdx1 regulates H-Ras effector pathways known to promote transformation, including PI3K/Akt, RalGEF or MAPK pathways (Li et al, 2004; Lim and Counter, 2005). Treatment of MEFs with H2O2 (50 muM) for increasing periods of time enhanced Akt phosphorylation on Ser473 (pAktSer473) and Thr308 (pAktThr308) at a higher level in Prdx1-/-MEFs compared with Prdx1+/+MEFs (Figure 2A). This finding correlated with a steady increase of PTEN oxidation over time in Prdx1-/-MEFs, whereas in Prdx1+/+MEFs PTEN oxidation plateaued after 6-8 min (Figure 2B and C). Phosphorylation of Akt on serine 473 (pAktSer473) and PTEN oxidation increased also in Prdx1-/- MEFs compared with Prdx1+/+MEFs when exposed to increasing amounts of H2O2 (Supplementary Figure S2A and B). Similar data were obtained by inducing H2O2 endogenously through treating cells with PDGF, as it led to a larger increase in (1) pAktSer473 and pAktThr308 (Figure 2D) and (2) PTEN oxidation in Prdx1-/-MEFs when compared with Prdx1+/+MEFs (Figure 2E). Although PTEN oxidation steadily increased in Prdx1-/-MEFs, it decreased in Prdx1+/+MEFs over time (Figure 2E and F). Levels of PAktSer473 and PTEN oxidation was also increased in Prdx1-/-MEFs compared with Prdx1+/+MEFs when exposed to increasing amounts of H2O2 or PDGF (Supplementary Figure S2A-D). Lastly, we confirmed that lack of Prdx1 enhanced basal and H2O2-induced phosphorylation of Akt substrates in Prdx1-/-MEFs more than in Prdx1+/+MEFs (Figure 2G).
###end p 13
###begin title 14
Prdx1 interacts with PTEN
###end title 14
###begin p 15
###xml 66 75 66 75 <xref ref-type="fig" rid="f3">Figure 3A</xref>
###xml 244 253 244 253 <xref ref-type="fig" rid="f3">Figure 3B</xref>
###xml 305 306 305 306 <sub>2</sub>
###xml 307 308 307 308 <sub>2</sub>
###xml 341 352 341 352 <sup>Cys51/72Ser</sup>
###xml 364 373 364 373 <xref ref-type="fig" rid="f3">Figure 3C</xref>
###xml 431 461 431 461 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure S3A and B</xref>
###xml 500 501 500 501 <sub>2</sub>
###xml 502 503 502 503 <sub>2</sub>
###xml 550 554 550 554 <sup>C51S</sup>
###xml 564 572 564 572 <sup>C51/172S</sup>
###xml 620 625 620 625 <sup>C172S</sup>
###xml 627 636 627 636 <xref ref-type="fig" rid="f3">Figure 3D</xref>
###xml 756 765 756 765 <xref ref-type="fig" rid="f3">Figure 3E</xref>
###xml 871 880 871 880 <xref ref-type="fig" rid="f3">Figure 3F</xref>
###xml 882 912 882 912 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure S3C and D</xref>
###xml 1022 1031 1022 1031 <xref ref-type="fig" rid="f3">Figure 3F</xref>
###xml 1053 1077 1053 1077 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure S3G</xref>
###xml 1152 1161 1152 1161 <xref ref-type="fig" rid="f3">Figure 3G</xref>
###xml 1261 1266 1261 1266 <italic>et al</italic>
###xml 1257 1272 1257 1272 <xref ref-type="bibr" rid="b15">Lee <italic>et al</italic>, 1999</xref>
###xml 1294 1299 1294 1299 <italic>et al</italic>
###xml 1284 1305 1284 1305 <xref ref-type="bibr" rid="b23">Matsumura <italic>et al</italic>, 2008</xref>
###xml 1600 1609 1600 1609 <xref ref-type="fig" rid="f3">Figure 3G</xref>
PTEN forms a complex with endogenous and epitope-tagged HA-Prdx1 (Figure 3A). This complex was regulated by oxidative stress, as co-expressed epitope-tagged Myc-PTEN and HA-Prdx1 dissociated under increasing concentrations of oxidative stress (Figure 3B, upper panel). In contrast, increasing dosages of H2O2 did not disrupt binding of Prdx1Cys51/72Ser with PTEN (Figure 3C). Immunoblotting confirmed equal expression of proteins (Supplementary Figure S3A and B). Peroxidatic Cys51 may regulate the H2O2-induced Prdx1:PTEN complex disruption as Prdx1C51S and Prdx1C51/172S proteins bind more to wild-type PTEN than Prdx1C172S (Figure 3D). We further confirmed a physical association between Prdx1 and PTEN by using GST-pull down of GST-Prdx1 and His-PTEN (Figure 3E). Mutational analysis suggested that Prdx1 interacts within the C2 domain of PTEN (amino acids 186-274) (Figure 3F; Supplementary Figure S3C and D) and PTEN with the N terminus of Prdx1 (amino acids 1-40) and the C terminus of Prdx1 (amino acids 157-199) (Figure 3F, lower schematic and Supplementary Figure S3G). Computational analysis allowed us to narrow those interaction surfaces (Figure 3G). The images of Prdx1 and PTEN were generated from coordinates from the protein database 1d5r (Lee et al, 1999) and 2z9s (Matsumura et al, 2008), respectively. As shown for PTEN, the region of 186-251 consists of two double-stranded anti-parallel sheets connected through two flexible loops. Similarly, the 1-40 region of Prdx1 consists of a single double-stranded anti-parallel sheet and another, surface exposed single sheet strand. In Figure 3G, the Prdx-1 protein is shown only as the monomer and the helical region that lies at the dimer interface, residues 183-199, are also positioned in a surface exposed position that is obviously well poised to mediate a protein-protein interaction. Deleting the identified interaction sites in PTEN and Prdx1 altered enzyme activity of both enzymes (data not shown), which did not allow us to study the role of a physical interaction in protecting PTEN lipid phosphatase activity.
###end p 15
###begin title 16
Prdx1 interaction with PTEN protects and promotes PTEN lipid phosphates activity under oxidative stress
###end title 16
###begin p 17
###xml 107 108 106 107 <sub>2</sub>
###xml 109 110 108 109 <sub>2</sub>
###xml 113 122 112 121 <xref ref-type="fig" rid="f4">Figure 4A</xref>
###xml 161 170 160 169 <xref ref-type="fig" rid="f3">Figure 3B</xref>
###xml 232 233 230 231 <sub>2</sub>
###xml 234 235 232 233 <sub>2</sub>
###xml 293 302 291 300 <xref ref-type="fig" rid="f3">Figure 3B</xref>
###xml 438 447 436 445 <xref ref-type="fig" rid="f4">Figure 4A</xref>
###xml 544 545 542 543 <sub>2</sub>
###xml 546 547 544 545 <sub>2</sub>
###xml 658 659 656 657 <sub>3</sub>
###xml 686 695 684 693 <xref ref-type="fig" rid="f4">Figure 4B</xref>
###xml 718 719 716 717 <sub>2</sub>
###xml 720 721 718 719 <sub>2</sub>
###xml 1142 1166 1140 1164 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure S3G</xref>
###xml 1185 1194 1183 1192 <xref ref-type="fig" rid="f3">Figure 3G</xref>
###xml 1311 1312 1309 1310 <sub>2</sub>
###xml 1313 1314 1311 1312 <sub>2</sub>
###xml 1356 1365 1354 1363 <xref ref-type="fig" rid="f4">Figure 4C</xref>
###xml 1489 1498 1487 1496 <xref ref-type="fig" rid="f4">Figure 4D</xref>
###xml 1666 1667 1664 1665 <sup>+</sup>
###xml 1914 1923 1912 1921 <xref ref-type="fig" rid="f4">Figure 4E</xref>
PTEN lipid phosphatase activity was fully protected by Prdx1 in cells under mild oxidative stress (25 muM H2O2) (Figure 4A), where Prdx1 was found to bind PTEN (Figure 3B). However, under higher oxidative stress treatment (500 muM H2O2), which resulted in decreased binding of PTEN and Prdx1 (Figure 3B), impaired PTEN's lipid phosphatase activity. Western blotting confirmed equal amounts of PTEN protein in the lipid phosphatase assay (Figure 4A, lower panel). To complement those results, we exposed recombinant purified His-tagged PTEN to H2O2 in the absence or presence of increasing amounts of purified recombinant Prdx1 and assayed PTEN for PI(3,4,5)P3 utilization. As expected (Figure 4B), in the presence of H2O2, we found that low molar amounts of Prdx1 protein weakly protected PTEN lipid phosphatase activity, whereas equimolar Prdx1 fully restored and further increases in Prdx1 protein amount did not enhance PTEN lipid phosphatase activity any more. Pre-incubation of PTEN in this assay with N-and C-terminal Prdx1 peptide replica (P1 and P2, respectively; peptide sequences were based on Prdx1 interaction mapping as shown in Supplementary Figure S3G and discussed for Figure 3G) decreased PTEN lipid phosphatase activity efficiently to 53%, which was comparable to PTEN activity observed with H2O2 treatment in the absence of Prdx1 (50%) (Figure 4C). Addition of P1 decreased PTEN lipid phosphatase activity only to 65%, whereas P2 lowered it to 57%. However, as shown in Figure 4D, the addition of His-purified PTEN to recombinant Prdx1 inhibited Prdx1 peroxidase activity. Under our experimental conditions, the kinetics of NADPH oxidation to NADP+ were linear and the Prdx1 inhibition was proportional to molar amount of PTEN and reached saturation (completed inhibition) at PTEN/Prdx1=1:1 (mol/mol) ratio. Moreover, an increase in PTEN ratio lowered the velocity of Prdx1 peroxidase activity (Figure 4E).
###end p 17
###begin title 18
Prdx1 suppresses H-Ras and ErbB-2-induced transformation mainly via promoting PTEN activity
###end title 18
###begin p 19
###xml 25 28 25 28 <sup>&#8722;/&#8722;</sup>
###xml 142 145 142 145 <sup>&#8722;/&#8722;</sup>
###xml 164 170 164 170 <sup>Ser473</sup>
###xml 180 181 180 181 <sub>2</sub>
###xml 182 183 182 183 <sub>2</sub>
###xml 230 233 230 233 <sup>&#8722;/&#8722;</sup>
###xml 246 249 246 249 <sup>+/+</sup>
###xml 255 264 255 264 <xref ref-type="fig" rid="f5">Figure 5A</xref>
###xml 352 355 352 355 <sup>&#8722;/&#8722;</sup>
###xml 378 381 378 381 <sup>&#8722;/&#8722;</sup>
###xml 492 493 492 493 <sub>2</sub>
###xml 494 495 494 495 <sub>2</sub>
###xml 507 516 507 516 <xref ref-type="fig" rid="f5">Figure 5B</xref>
###xml 613 618 613 618 <italic>et al</italic>
###xml 602 624 602 624 <xref ref-type="bibr" rid="b22">Maroulakou <italic>et al</italic>, 2007</xref>
###xml 697 700 697 700 <sup>+/&#8722;</sup>
###xml 711 716 711 716 <italic>et al</italic>
###xml 706 722 706 722 <xref ref-type="bibr" rid="b3">Chen <italic>et al</italic>, 2006</xref>
###xml 745 754 745 754 <xref ref-type="fig" rid="f1">Figure 1B</xref>
###xml 762 764 762 764 <sup>WT</sup>
###xml 853 877 853 877 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure S5A</xref>
###xml 950 953 950 953 <sup>&#8722;/&#8722;</sup>
###xml 1080 1091 1080 1091 <xref ref-type="fig" rid="f5">Figure 5C&#8211;E</xref>
###xml 1128 1140 1128 1140 <sup>&#8722;/&#8722;;H&#8722;RasV12</sup>
###xml 1152 1167 1152 1167 <sup>&#8722;/&#8722;;ErbB&#8722;2/neuT</sup>
###xml 1225 1240 1225 1240 <sup>&#8722;/&#8722;;H&#8722;Ras;pMKO1</sup>
###xml 1252 1272 1252 1272 <sup>&#8722;/&#8722;ErbB&#8722;2/neuT;pMKO1</sup>
###xml 1285 1314 1285 1314 <sup>&#8722;/&#8722;;shPrdx1;GFP&#8722;PTEN,H&#8722;RasV12</sup>
###xml 1382 1409 1382 1409 <sup>&#8722;/&#8722;;pMKO1;GFP&#8722;PTEN,H&#8722;RasV12</sup>
###xml 1422 1454 1422 1454 <sup>&#8722;/&#8722;;shPrdx1;GFP&#8722;PTEN,ErbB&#8722;2/neuT</sup>
###xml 1520 1550 1520 1550 <sup>&#8722;/&#8722;;pKMO1;GFP&#8722;PTEN;ErbB&#8722;2/neuT</sup>
###xml 1623 1641 1623 1641 <sup>&#8722;/&#8722;;pMKO1;H&#8722;RasV12</sup>
###xml 1664 1685 1664 1685 <sup>&#8722;/&#8722;;GFP&#8722;PTEN;H&#8722;RasV12</sup>
###xml 1701 1722 1701 1722 <sup>&#8722;/&#8722;;pMKO1;ErbB&#8722;2/neuT</sup>
###xml 1745 1769 1745 1769 <sup>&#8722;/&#8722;;GFP&#8722;PTEN;ErbB&#8722;2/neuT</sup>
###xml 1885 1886 1885 1886 <sub>2</sub>
###xml 1887 1888 1887 1888 <sub>2</sub>
###xml 1918 1921 1918 1921 <sup>&#8722;/&#8722;</sup>
###xml 1956 1959 1956 1959 <sup>+/+</sup>
###xml 1965 1989 1965 1989 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure S5B</xref>
###xml 2138 2141 2138 2141 <sup>&#8722;/&#8722;</sup>
###xml 2165 2168 2165 2168 <sup>+/+</sup>
###xml 2174 2181 2174 2181 <xref ref-type="table" rid="t1">Table I</xref>
###xml 2205 2217 2205 2217 <sup>&#8722;/&#8722;;H&#8722;RasV12</sup>
###xml 2294 2306 2294 2306 <sup>+/+;H&#8722;RasV12</sup>
###xml 2338 2339 2338 2339 <italic>P</italic>
###xml 2401 2413 2400 2412 <sup>&#8722;/&#8722;;H&#8722;RasV21</sup>
###xml 2451 2463 2450 2462 <sup>+/+;H&#8722;RasV12</sup>
###xml 2527 2542 2525 2540 <sup>&#8722;/&#8722;;ErbB&#8722;2/neuT</sup>
###xml 2576 2591 2574 2589 <sup>+/+;ErbB&#8722;2/neuT</sup>
###xml 2667 2682 2664 2679 <sup>&#8722;/&#8722;;ErbB&#8722;2/neuT</sup>
###xml 2696 2711 2693 2708 <sup>+/+;ErbB&#8722;2/neuT</sup>
###xml 700 704 <span type="species:ncbi:10090">mice</span>
Next, we examined in PTEN-/-MEFs whether Prdx1 has an important function in PTEN-induced tumour suppression. Although Prdx1 knock down in PTEN-/-MEFs decreased pAktSer473 levels, H2O2 treatment of MEFs increased it equally in PTEN-/-MEFs and PTEN+/+MEFs (Figure 5A). Prdx1 is neither over-oxidized nor does it form less peroxidase active dimers in PTEN-/-MEFs compared with PTEN-/-MEFs reconstituted with GFP-PTEN, suggesting that in PTEN-null cells, Prdx1 activity is not compromised after H2O2 treatment (Figure 5B). PI3K/Akt signalling is also essential for oncogenic ErbB-2-induced transformation (Maroulakou et al, 2007), and Akt1 deficiency sufficiently suppresses tumour development in PTEN+/-mice (Chen et al, 2006). As shown for H-Ras (Figure 1B), Prdx1WT also prevented ErbB-2/neuT-induced transformation depending on its peroxidase activity (Supplementary Figure S5A). By using small hairpin (sh) RNA targeting Prdx1 mRNA (shPrdx1) in PTEN-/-MEFs, transformed by either H-RasV12 or ErbB-2/neuT, we showed that Prdx1 suppressed transformation mainly by regulating PTEN (Figure 5C-E). Although shPrdx1 expressed in PTEN-/-;H-RasV12MEFs or PTEN-/-;ErbB-2/neuT MEFs did not increase colony formation compared with PTEN-/-;H-Ras;pMKO1MEFs or PTEN-/-ErbB-2/neuT;pMKO1MEFs, in PTEN-/-;shPrdx1;GFP-PTEN,H-RasV12MEFs showed 1.5-fold increase in colony formation compared with PTEN-/-;pMKO1;GFP-PTEN,H-RasV12MEFs and PTEN-/-;shPrdx1;GFP-PTEN,ErbB-2/neuTMEFs and 1.35-fold increase in colony formation compared with PTEN-/-;pKMO1;GFP-PTEN;ErbB-2/neuTMEFs. Furthermore, a slight increase of Prdx1 oxidation was noted in PTEN-/-;pMKO1;H-RasV12MEFs compared with PTEN-/-;GFP-PTEN;H-RasV12MEFs and in PTEN-/-;pMKO1;ErbB-2/neuTMEFs compared with PTEN-/-;GFP-PTEN;ErbB-2/neuTMEFs. By using minimum dosages of two well-known PI3K inhibitors, Wortmannin (WM) and Ly294002 (Ly) that inhibited H2O2-induced Akt activity in Prdx1-/-MEFs less efficiently than in Prdx1+/+MEFs (Supplementary Figure S5B), we found that partial inhibition of PI3K/Akt activity translates into less efficient inhibition of H-Ras or ErbB-2-induced transformation in Prdx1-/-MEFs compared with Prdx1+/+MEFs (Table I): 5 nM WM reduced Prdx1-/-;H-RasV12MEFs colony number by <4%, 10 nM WM by 2.3%. However, 5 nM WM decreased Prdx1+/+;H-RasV12MEFs colony numbers by 46% and (P=<0.001) 10 nM WM by 67%. Similarly, 10 muM Ly decreased Prdx1-/-;H-RasV21MEFs colony number by 61% and in Prdx1+/+;H-RasV12MEFs by 73%. However, 10 muM Ly decreased colony number of Prdx1-/-;ErbB-2/neuTMEFs by only 53%, whereas in Prdx1+/+;ErbB-2/neuTMEFs by 75%. Moreover, 25 muM Ly decreased colony formation equally in Prdx1-/-;ErbB-2/neuTMEFs and Prdx1+/+;ErbB-2/neuTMEFs to 4-5%.
###end p 19
###begin title 20
Loss of Prdx1 promotes H-Ras-induced mammary tumours and PTEN oxidation in mammary epithelial cells
###end title 20
###begin p 21
###xml 175 180 175 180 <italic>et al</italic>
###xml 170 186 170 186 <xref ref-type="bibr" rid="b36">Sinn <italic>et al</italic>, 1987</xref>
###xml 264 269 264 269 <italic>et al</italic>
###xml 253 275 253 275 <xref ref-type="bibr" rid="b22">Maroulakou <italic>et al</italic>, 2007</xref>
###xml 363 370 363 370 <italic>in vivo</italic>
###xml 372 381 372 381 <xref ref-type="fig" rid="f6">Figure 6A</xref>
###xml 412 415 412 415 <sup>+/+</sup>
###xml 530 533 530 533 <sup>+/&#8722;</sup>
###xml 602 604 602 604 <sub>50</sub>
###xml 783 786 783 786 <sup>&#8722;/&#8722;</sup>
###xml 794 796 794 796 <sub>50</sub>
###xml 881 887 881 887 <sup>Ser473</sup>
###xml 1023 1032 1023 1032 <xref ref-type="fig" rid="f6">Figure 6B</xref>
###xml 1042 1048 1042 1048 <sup>Ser473</sup>
###xml 1050 1059 1050 1059 <xref ref-type="fig" rid="f6">Figure 6C</xref>
###xml 0 4 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 13 17 <span type="species:ncbi:10090">mice</span>
###xml 18 33 <span type="species:ncbi:10090">transgenic mice</span>
###xml 247 251 <span type="species:ncbi:10090">mice</span>
###xml 416 420 <span type="species:ncbi:10090">mice</span>
###xml 534 538 <span type="species:ncbi:10090">mice</span>
###xml 755 759 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 768 772 <span type="species:ncbi:10090">mice</span>
###xml 940 944 <span type="species:ncbi:10090">mice</span>
MMTV/v-H-Ras mice transgenic mice are highly susceptible to mammary carcinomas due to the targeted over-expression of the activated Ras oncogene in their mammary glands (Sinn et al, 1987) and Akt1 ablation lowers the incidence of tumours in these mice (Maroulakou et al, 2007). In our experiment, we confirmed that Prdx1 plays a role in Ras-induced tumorigenesis in vivo (Figure 6A). In all, 60% of the Ras/Prdx1+/+ mice remained tumour free during the entire observation period of 36 weeks. In contrast, only 40% of the Ras/Prdx1+/- mice remained tumour free during that time with a median survival (T50) of 28 weeks, which indicated that the loss of one copy of Prdx1 accelerated Ras-induced breast cancer. Moreover, eliminating both copies of Prdx1 in MMTV/v-H-Ras mice (Ras/Prdx1-/-), the T50 for breast cancer was only 20 weeks. We then evaluated basal PTEN oxidation and pAktSer473 in mammary epithelial cells (MECs) from 16-week-old mice that had not developed tumours. Lack of Prdx1 increased basal PTEN oxidation (Figure 6B) and pAktSer473 (Figure 6C).
###end p 21
###begin title 22
Discussion
###end title 22
###begin p 23
###xml 62 63 62 63 <sub>2</sub>
###xml 64 65 64 65 <sub>2</sub>
###xml 91 92 91 92 <italic>K</italic>
###xml 92 93 92 93 <sub>M</sub>
###xml 100 105 100 105 <italic>et al</italic>
###xml 95 112 95 112 <xref ref-type="bibr" rid="b1">Chae <italic>et al</italic>, 1994a</xref>
###xml 121 126 121 126 <italic>et al</italic>
###xml 114 132 114 132 <xref ref-type="bibr" rid="b21">Loewen <italic>et al</italic>, 2004</xref>
###xml 160 161 160 161 <sub>2</sub>
###xml 162 163 162 163 <sub>2</sub>
###xml 238 239 238 239 <sub>2</sub>
###xml 240 241 240 241 <sub>2</sub>
###xml 279 288 279 288 <xref ref-type="fig" rid="f1">Figure 1A</xref>
###xml 293 317 293 317 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure S1A</xref>
###xml 384 387 384 387 <sup>V12</sup>
###xml 389 398 389 398 <xref ref-type="fig" rid="f1">Figure 1B</xref>
###xml 416 440 416 440 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure S5A</xref>
###xml 626 631 626 631 <italic>et al</italic>
###xml 623 637 623 637 <xref ref-type="bibr" rid="b9">Ho <italic>et al</italic>, 1997</xref>
###xml 861 883 861 883 <xref ref-type="bibr" rid="b42">Wen and VanEtten, 1997</xref>
###xml 916 921 916 921 <italic>et al</italic>
###xml 912 927 912 927 <xref ref-type="bibr" rid="b12">Kim <italic>et al</italic>, 2006</xref>
###xml 958 967 958 967 <xref ref-type="fig" rid="f3">Figure 3B</xref>
###xml 1048 1053 1048 1053 <italic>et al</italic>
###xml 1040 1059 1040 1059 <xref ref-type="bibr" rid="b27">Neumann <italic>et al</italic>, 1998</xref>
###xml 1074 1079 1074 1079 <italic>et al</italic>
###xml 1070 1085 1070 1085 <xref ref-type="bibr" rid="b12">Kim <italic>et al</italic>, 2006</xref>
###xml 1387 1396 1387 1396 <xref ref-type="fig" rid="f4">Figure 4B</xref>
###xml 1411 1419 1411 1419 <sup>C51/172S</sup>
###xml 1470 1475 1470 1475 <italic>et al</italic>
###xml 1465 1482 1465 1482 <xref ref-type="bibr" rid="b2">Chae <italic>et al</italic>, 1994b</xref>
###xml 1529 1530 1529 1530 <sub>2</sub>
###xml 1531 1532 1531 1532 <sub>2</sub>
###xml 1544 1553 1544 1553 <xref ref-type="fig" rid="f3">Figure 3C</xref>
###xml 499 503 <span type="species:ncbi:10090">mice</span>
###xml 550 554 <span type="species:ncbi:10090">mice</span>
Compared with Prdxs, catalase peroxidase activity decomposes H2O2 with a >1000-fold higher KM (Chae et al, 1994a; Loewen et al, 2004) and therefore eliminates H2O2 with much higher efficiency. Thus, we cannot expect that Prdx1 scavenges H2O2 in considerable amounts, as shown in Figure 1A and Supplementary Figure S1A. Yet, Prdx1's peroxidase activity is important in preventing H-RasV12 (Figure 1B) or ErbB-2/neuT (Supplementary Figure S5A) induced transformation. Similar to the catalase knockout mice, all other currently published Prdxs knockout mice, show phenotypically no increased susceptibility to transformation (Ho et al, 1997). Therefore, Prdx1 may have a unique function amongst cellular peroxidases in tumour suppression, by affecting signalling directly through physical interaction with target enzymes. This was shown for c-Abl tyrosine kinase (Wen and VanEtten, 1997) and c-Jun terminal kinase (Kim et al, 2006). As described here for PTEN (Figure 3B), oxidative stress induced Prdx1 to dissociate, which in case of c-Abl (Neumann et al, 1998) and JNK (Kim et al, 2006) resulted in kinase activation. The Prdx1:PTEN heterodimer is most likely formed in a 1:1 molar ratio, as (1) the Prdx1 preservation of PTEN lipid phosphatase activity under oxidative stress is achieved by a 1:1 (mol:mol) ratio of Prdx1 and PTEN and could not be further increased by excess of Prdx1 (Figure 4B) and (2) Prdx1C51/172S, which is unable to form dimeric structures (Chae et al, 1994b), bound to PTEN and did not dissociate under H2O2 treatment (Figure 3C). Therefore, these data provide compelling evidence that Prdx1 may bind PTEN as a monomer.
###end p 23
###begin p 24
###xml 121 130 121 130 <xref ref-type="fig" rid="f4">Figure 4C</xref>
###xml 287 302 287 302 <xref ref-type="fig" rid="f3">Figure 3F and G</xref>
###xml 304 328 304 328 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure S3E</xref>
###xml 347 348 347 348 <sub>2</sub>
###xml 349 350 349 350 <sub>2</sub>
###xml 442 443 442 443 <sub>2</sub>
###xml 444 445 444 445 <sub>2</sub>
###xml 487 496 487 496 <xref ref-type="fig" rid="f4">Figure 4C</xref>
###xml 593 594 593 594 <sub>2</sub>
###xml 595 596 595 596 <sub>2</sub>
###xml 712 721 712 721 <xref ref-type="fig" rid="f3">Figure 3D</xref>
###xml 1020 1025 1020 1025 <italic>et al</italic>
###xml 1011 1031 1011 1031 <xref ref-type="bibr" rid="b33">Schroder <italic>et al</italic>, 2000</xref>
###xml 1043 1048 1043 1048 <italic>et al</italic>
###xml 1033 1054 1033 1054 <xref ref-type="bibr" rid="b23">Matsumura <italic>et al</italic>, 2008</xref>
###xml 1106 1107 1106 1107 <sub>2</sub>
###xml 1108 1109 1108 1109 <sub>2</sub>
We further propose that the Prdx1:PTEN interaction is essential for protecting PTEN from oxidation-induced inactivation (Figure 4C), as Prdx1 C- and N-terminal peptide replica, which were designed based on our mapping studies and computer modelling to block PTEN docking sites on Prdx1 (Figure 3F and G; Supplementary Figure S3E), resulted after H2O2 treatment in a 47% reduction of PTEN activity. This was comparable to PTEN activity after H2O2 treatment in the absence of Prdx1 (50%) (Figure 4C). The Prdx1 N terminus, which includes Cys51, may have an important function in regulating the H2O2-induced dissociation of the Prdx1:PTEN complex, as Cys51 when replaced by a serine enhances Prdx1 binding to PTEN (Figure 3D). X-ray crystallography of Prdxs suggested significant conformational changes, such as unwinding of the active site N-terminal helix, to form disulfides, as in reduced Prdxs, the sulfur atoms of the N- and C-terminal conserved cysteine residues are too far apart to react with each other (Schroder et al, 2000; Matsumura et al, 2008). Therefore, in the Prdx1:PTEN complex, increased H2O2 may oxidize Cys51 (Prdx1), thus, promoting unwinding of the PTEN-binding conformation of Prdx1 consequently inducing dissociation.
###end p 24
###begin p 25
###xml 106 111 106 111 <italic>et al</italic>
###xml 101 117 101 117 <xref ref-type="bibr" rid="b44">Yang <italic>et al</italic>, 2002</xref>
###xml 246 247 246 247 <sub>2</sub>
###xml 248 249 248 249 <sub>2</sub>
###xml 415 430 415 430 <xref ref-type="fig" rid="f4">Figure 4C and D</xref>
###xml 662 667 662 667 <italic>et al</italic>
###xml 653 673 653 673 <xref ref-type="bibr" rid="b24">Meuillet <italic>et al</italic>, 2004</xref>
Over-oxidation of Prdx1 Cys51 occurs during catalysis and correlates with increasing amounts of Trx (Yang et al, 2002). The reduction of Cys51 by Trx inhibits the folding back of Cys51 into its pocket thereby exposing it to further oxidation by H2O2. The binding of PTEN to Prdx1 could have similar effects on Prdx1, thereby inhibiting sufficient reduction of Cys51 by Trx and decreasing Prdx1 peroxidase activity (Figure 4C and D). Alternatively, as it has been shown that Trx binds PTEN and inactivates its lipid phosphates activity, it could be that under our experimental conditions Trx is depleted from the Prdx1 scavenging system by binding PTEN (Meuillet et al, 2004). This seems unlikely though, as Trx was added in approximately 300-fold molar excess, which should provide a large Trx pool to reduce oxidized Prdx1 proteins.
###end p 25
###begin p 26
###xml 81 90 81 90 <xref ref-type="fig" rid="f3">Figure 3F</xref>
###xml 92 122 92 122 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure S3D and E</xref>
###xml 328 333 328 333 <italic>et al</italic>
###xml 324 339 324 339 <xref ref-type="bibr" rid="b4">Das <italic>et al</italic>, 2003</xref>
###xml 544 549 544 549 <italic>et al</italic>
###xml 535 555 535 555 <xref ref-type="bibr" rid="b28">Pasquali <italic>et al</italic>, 2007</xref>
###xml 744 749 744 749 <italic>et al</italic>
###xml 736 755 736 755 <xref ref-type="bibr" rid="b40">Vazquez <italic>et al</italic>, 2006</xref>
###xml 816 837 816 837 <xref ref-type="fig" rid="f2">Figure 2B, C, E and F</xref>
###xml 839 869 839 869 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure S2B and D</xref>
###xml 946 947 946 947 <sub>2</sub>
###xml 948 949 948 949 <sub>2</sub>
###xml 964 969 964 969 <italic>et al</italic>
###xml 959 975 959 975 <xref ref-type="bibr" rid="b14">Kwon <italic>et al</italic>, 2004</xref>
###xml 992 993 992 993 <sub>2</sub>
###xml 994 995 994 995 <sub>2</sub>
###xml 1132 1142 1132 1142 <xref ref-type="bibr" rid="b32">Rhee, 2006</xref>
###xml 1174 1179 1174 1179 <italic>et al</italic>
###xml 1167 1185 1167 1185 <xref ref-type="bibr" rid="b17">Leslie <italic>et al</italic>, 2003</xref>
###xml 1261 1262 1261 1262 <sub>3</sub>
###xml 1343 1344 1343 1344 <sub>3</sub>
###xml 1435 1436 1435 1436 <sub>3</sub>
###xml 1568 1569 1568 1569 <sub>3</sub>
###xml 1638 1640 1638 1640 <sup>WT</sup>
###xml 1647 1652 1647 1652 <italic>et al</italic>
###xml 1642 1658 1642 1658 <xref ref-type="bibr" rid="b14">Kwon <italic>et al</italic>, 2004</xref>
We defined a novel interaction site of Prdx1 with PTEN in the C2 domain of PTEN (Figure 3F; Supplementary Figure S3D and E), which together with the N-terminal PTD, are both required for enzyme activity. Surface plasmon resonance analysis revealed that the C2 domain is essential for high-affinity membrane binding of PTEN (Das et al, 2003). Our data support this finding, as it has been shown recently through chemical proteomic strategy using cleavable lipid baits, that Prdx1 is a potential novel phosphoinositides-binding protein (Pasquali et al, 2007). Prdx1 may, therefore, stabilize PTEN binding to the plasma membrane, which in a recent analysis using single-molecule TIRF microscopy, lasts only for a few hundred milliseconds (Vazquez et al, 2006). Such short time of membrane binding could explain why we (Figure 2B, C, E and F; Supplementary Figure S2B and D) and others see only small amounts of PTEN oxidized after cell exposure to H2O2 or PDGF (Kwon et al, 2004). PDGF-induced H2O2 stems either from metabolized superoxide released by NADPH oxidases (NOXs) or the mitochondria and is considered a signalling molecule (Rhee, 2006). As discussed earlier (Leslie et al, 2003), such finding may be attributed to the proximity of NOXs complexes and PIP3. Over-expression of Nox1, in PDGF-stimulated NIH 3T3 cells rapidly increases PIP3 levels, in contrast to PI3K activity, suggesting that Nox1-induced superoxide enhances PIP3 levels by inactivating PTEN rather than activating PI3K. Expression of a peroxidase inactive Prdx2 leads to a rapid increase of PIP3 levels in growth factor stimulated cells, which is reversed by Prdx2WT (Kwon et al, 2004). In our hands however, Prdx2 did not bind PTEN, as we were unable to detect an interaction of Prdx2 and PTEN by immunoprecipitation (data not shown).
###end p 26
###begin p 27
###xml 81 106 81 106 <xref ref-type="bibr" rid="b39">Tolkacheva and Chan, 2000</xref>
###xml 113 118 113 118 <italic>et al</italic>
###xml 108 124 108 124 <xref ref-type="bibr" rid="b13">Koul <italic>et al</italic>, 2002</xref>
###xml 252 257 252 257 <italic>et al</italic>
###xml 246 263 246 263 <xref ref-type="bibr" rid="b37">Skeen <italic>et al</italic>, 2006</xref>
###xml 276 281 276 281 <italic>et al</italic>
###xml 265 287 265 287 <xref ref-type="bibr" rid="b22">Maroulakou <italic>et al</italic>, 2007</xref>
###xml 341 342 341 342 <sub>2</sub>
###xml 343 344 343 344 <sub>2</sub>
###xml 376 394 376 394 <xref ref-type="fig" rid="f2">Figure 2A, D and G</xref>
###xml 504 513 504 513 <xref ref-type="fig" rid="f1">Figure 1B</xref>
###xml 515 539 515 539 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure S5A</xref>
###xml 659 665 659 665 <sup>Ser473</sup>
###xml 710 721 710 721 <xref ref-type="fig" rid="f6">Figure 6A&#8211;C</xref>
###xml 836 839 836 839 <sup>&#8722;/&#8722;</sup>
###xml 914 929 914 929 <xref ref-type="fig" rid="f5">Figure 5C and D</xref>
###xml 1156 1188 1156 1188 <sup>&#8722;/&#8722;;shPrdx1;GFP&#8722;PTEN;ErbB&#8722;2/neuT</sup>
###xml 1211 1240 1211 1240 <sup>&#8722;/&#8722;;shPrdx1;GFP&#8722;PTEN;H&#8722;RasV12</sup>
###xml 1328 1343 1328 1343 <xref ref-type="fig" rid="f5">Figure 5B and E</xref>
###xml 154 158 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 171 175 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 197 201 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 210 214 <span type="species:ncbi:10090">mice</span>
###xml 613 617 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 626 630 <span type="species:ncbi:10090">mice</span>
###xml 704 708 <span type="species:ncbi:10090">mice</span>
PTEN lipid phosphatase activity has an important function in tumour suppression (Tolkacheva and Chan, 2000; Koul et al, 2002) and Akt1 ablation protects (MMTV)-ErbB2/neu, MMTV-polyoma middle T and MMTV-v-H-Ras mice from breast cancer initiation (Skeen et al, 2006; Maroulakou et al, 2007). Here, we show that loss of Prdx1 increased basal, H2O2 and PDGF-induced Akt activity (Figure 2A, D and G) and Prdx1 peroxidase activity was essential in suppressing H-Rasv12 and ErbB-2/neuT-induced transformation (Figure 1B; Supplementary Figure S5A). Along those lines, Prdx1 ablation accelerated mammary tumorigenesis in MMTV-v-H-Ras mice and increased levels of pAktSer473 and PTEN oxidation in MECs from these mice (Figure 6A-C). Prdx1 tumour suppression seemed to occur largely via regulation of the PTEN and Akt. Knock down of Prdx1 in PTEN-/-MEFs did not significantly enhance H-Ras or ErbB-2-induced transformation (Figure 5C and D), whereas in transformed PTEN-containing MEFs, decrease in Prdx1 levels resulted in a gain of transformation: 1.5-fold for H-RasV12 and only 1.35-fold for ErbB-2/neuT, which we contributed to decreased Prdx1 knock down in PTEN-/-;shPrdx1;GFP-PTEN;ErbB-2/neuTMEFs compared with PTEN-/-;shPrdx1;GFP-PTEN;H-RasV12MEFs). Lack of PTEN also did not result in Prdx1 over-oxidation nor reduced expression (Figure 5B and E), suggesting that in PTEN-deficient cells, Prdx1 is acting as peroxidase.
###end p 27
###begin p 28
###xml 90 91 90 91 <sub>2</sub>
###xml 92 93 92 93 <sub>2</sub>
###xml 168 169 168 169 <sub>3</sub>
###xml 186 187 186 187 <sub>2</sub>
###xml 189 214 189 214 <xref ref-type="bibr" rid="b41">Vivanco and Sawyers, 2002</xref>
###xml 279 284 279 284 <italic>et al</italic>
###xml 272 290 272 290 <xref ref-type="bibr" rid="b17">Leslie <italic>et al</italic>, 2003</xref>
###xml 297 308 297 308 <sup>&#8722;/&#8722;;shPrdx1</sup>
###xml 334 340 334 340 <sup>Ser473</sup>
###xml 366 369 366 369 <sup>&#8722;/&#8722;</sup>
###xml 375 384 375 384 <xref ref-type="fig" rid="f5">Figure 5D</xref>
###xml 447 448 447 448 <sub>2</sub>
###xml 449 450 449 450 <sub>2</sub>
###xml 462 463 462 463 <sub>2</sub>
###xml 464 465 464 465 <sub>2</sub>
###xml 483 494 483 494 <sup>&#8722;/&#8722;;shPrdx1</sup>
###xml 513 519 513 519 <sup>Ser473</sup>
###xml 545 548 545 548 <sup>&#8722;/&#8722;</sup>
###xml 574 575 574 575 <sub>2</sub>
###xml 576 577 576 577 <sub>2</sub>
###xml 608 629 608 629 <xref ref-type="bibr" rid="b31">Rao and Clayton, 2002</xref>
###xml 681 704 681 704 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure 2E</xref>
###xml 803 806 803 806 <sup>&#8722;/&#8722;</sup>
###xml 865 872 865 872 <xref ref-type="table" rid="t1">Table I</xref>
###xml 874 897 874 897 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure 5B</xref>
###xml 919 922 919 922 <sup>+/+</sup>
However, we have to consider the regulation of other phosphatases or kinases by Prdx1 or H2O2 in Akt-driven tumorigenesis. SHIP-1 and 2 are known to dephosphorylate PIP3 to PtdIns (3,4)P2 (Vivanco and Sawyers, 2002). However, SHIP2 is not inactivated by oxidative stress (Leslie et al, 2003). PTEN-/-;shPrdx1MEFs showed decreased pAKTSer473 levels compared with PTEN-/-MEFs (Figure 5D), perhaps due to the activation of SHIP2 by small amounts of H2O2. However, H2O2 treatment of PTEN-/-;shPrdx1MEFs increased pAKTSer473 levels comparable to PTEN-/-MEFs, suggesting maybe a H2O2-induced inactivation of PP2A (Rao and Clayton, 2002), as loss of Prdx1 also inactivated PP2A activity (Supplementary Figure 2E). We also cannot exclude a regulation of PI3K by Prdx1, as H-Ras and ErbB-2/neuT transformed Prdx1-/-MEFs display a lesser sensitivity towards PI3K inhibitors (Table I; Supplementary Figure 5B), compared with Prdx1+/+MEFs.
###end p 28
###begin p 29
###xml 219 220 219 220 <sub>2</sub>
###xml 221 222 221 222 <sub>2</sub>
In summary, oxidative stress and carcinogenesis are closely linked, however, molecular details, especially how oxidative stress promotes pro-oncogenic signalling pathways are scarce. Our studies shed some light on how H2O2 can promote oncogenic Ras and ErbB-2 signalling by providing evidence for the first time that the tumour suppressive function of PTEN and Prdx1 are closely related. The mechanistic details of the Prdx1 and PTEN interaction and its regulation in terms of Prdx1 peroxidase activity and PTEN oxidation will be important in future work.
###end p 29
###begin title 30
Materials and methods
###end title 30
###begin title 31
Reagents
###end title 31
###begin p 32
###xml 414 415 414 415 <sub>2</sub>
###xml 419 420 419 420 <sub>3</sub>
###xml 773 789 773 789 <italic>Escherichia coli</italic>
###xml 773 794 <span type="species:ncbi:511693">Escherichia coli BL21</span>
All chemicals were purchased from Sigma Aldrich unless otherwise indicated. Ly294002, WM, antibodies against PTEN (138G6), Akt (11-E7), Akt-phosphoserine 473 (193H12), Akt-phosphothreonine 308 (244F9), phospho Akt substrate (110B7E) and HA-tag were purchased from Cell Signaling; Antibodies recognizing PTEN (A2B1), PTEN (N-19) and Actin (C-11) were purchased from Santa Cruz; antibodies against Prdx1 and Prdx1-SO2/-SO3 were purchased from Abcam; Ras antibody from Oncogene; ErbB-2 antibody from Biosource. HA-conjugated agarose beads were purchased from Roche. Amplex Red reagent: Molecular Probes. DMEM, FBS, Glutamax, NEAA, Pen/Strep, Sodium Pyruvate, DMEM without Phenol Red, PBS and PDGF stem from Invitrogen; GST-sepharose from Pharmacia. 6His-PTEN was expressed in Escherichia coli BL21 from the fusion vector pProEx HTb PTEN and purified by standard protocols.
###end p 32
###begin title 33
Retrovirus
###end title 33
###begin p 34
The retrovirus was generated after conducting a transient transfection of retroviral constructs into a 293T/17 (ATCC) ecotropic-packaging cell line. Retroviral infection of MEFs was carried out for 4-6 h in the presence of 8 mug/ml polybrene. An antibiotic selection was carried out 24 h later until all uninfected cells were eliminated and stable polyclonal cell lines were generated.
###end p 34
###begin title 35
Generation of MEFs
###end title 35
###begin p 36
###xml 30 33 30 33 <sup>+/&#8722;</sup>
###xml 162 167 162 167 <italic>et al</italic>
###xml 154 173 154 173 <xref ref-type="bibr" rid="b26">Neumann <italic>et al</italic>, 2003</xref>
###xml 324 329 324 329 <italic>et al</italic>
###xml 319 335 319 335 <xref ref-type="bibr" rid="b8">Hahn <italic>et al</italic>, 2002</xref>
MEFs were generated from Prdx1+/- littermate matings in a C57BL/6J/129Sv background. Primary MEFs were harvested from E13.5 embryos as described earlier (Neumann et al, 2003). Primary Prdx1 and PTEN MEFs (passages 3-4) were immortalized by retroviral infection with pBabe-hygro DD p53 expressing dominant-negative p53 (Hahn et al, 2002) and selected with 150 mug/ml hygromycin for 14 days.
###end p 36
###begin title 37
Amplex red assay
###end title 37
###begin p 38
###xml 35 36 35 36 <italic>n</italic>
###xml 417 418 411 412 <sub>0</sub>
###xml 595 596 589 590 <sub>2</sub>
###xml 597 598 591 592 <sub>2</sub>
###xml 232 237 <span type="species:ncbi:9796">horse</span>
###xml 238 244 <span type="species:ncbi:3726">radish</span>
In total, 35 000 MEFs were plated (n=6) in 24-well plates (Costar 24) coated with fibronectin. On the day of the assay, cells were washed with PBS and repleted with serum-free and phenol red-free DMEM medium. Amplex Red reagent and horse radish peroxidase (HRP) were prepared as recommended by the manufacturer (HRP 0.2 U/ml). MEFs were incubated with Amplex Red/HRP solution at 37degreesC before the first reading (T0) at 540 nm on a plate reader (Molecular Devices SpectraMax M5). Plates were kept in an incubator between readings. The resulting fluorescence (FLU) was compared with FLU from H2O2 standard curves and analysed.
###end p 38
###begin title 39
Soft agar assays
###end title 39
###begin p 40
###xml 30 33 30 33 <sup>&#8722;/&#8722;</sup>
###xml 40 43 40 43 <sup>+/+</sup>
###xml 98 100 98 100 <sup>WT</sup>
###xml 109 117 109 117 <sup>C172/51S</sup>
###xml 280 283 279 282 <sup>V12</sup>
###xml 301 304 300 303 <sup>V12</sup>
###xml 310 315 309 314 <italic>et al</italic>
###xml 307 321 306 320 <xref ref-type="bibr" rid="b45">Yu <italic>et al</italic>, 2001</xref>
###xml 367 372 366 371 <italic>et al</italic>
###xml 364 378 363 377 <xref ref-type="bibr" rid="b45">Yu <italic>et al</italic>, 2001</xref>
P53DD-immortalized MEFs (Prdx1-/-, Prdx1+/+) were infected with retrovirus containing either Prdx1WT or Prdx1C172/51S, both subcloned into pQCXI-puro (Clontech) and selected 10 days in puromycin 2 mug/ml. Some clones were further infected with a retrovirus containing either H-RasV12 (pBabe-puro H-RasV12) (Yu et al, 2001) or wild-type ErbB-2 (pBabe-puro ErbB-2) (Yu et al, 2001) and selected in 5 mug/ml puromycin for another 5 days. MEFs were then resuspended in DMEM containing 0.53% agarose (Difco) and plated onto a layer of 0.7% agarose-containing medium in 3.5-cm plates in duplicate (10 000 cells per plate). Colonies were counted after 14-21 days.
###end p 40
###begin title 41
Akt activity and PTEN oxidation
###end title 41
###begin p 42
###xml 14 15 14 15 <sup>5</sup>
###xml 118 119 118 119 <sub>2</sub>
###xml 120 121 120 121 <sub>2</sub>
###xml 225 230 223 228 <italic>et al</italic>
###xml 218 236 216 234 <xref ref-type="bibr" rid="b17">Leslie <italic>et al</italic>, 2003</xref>
###xml 524 525 519 520 <italic>N</italic>
###xml 552 558 <span type="species:ncbi:9913">bovine</span>
MEFs (1.8 x 105) were plated on 10-cm plates and serum-starved (0.25% FBS) for 48 h. Plates were then incubated with H2O2 (+/-Ly294002 or WM) as indicated. Akt and PTEN protein analysis were done as described earlier (Leslie et al, 2003) with slight modifications. Briefly, lysis buffer (50 mM Tris pH 7.4; 1% Triton 100; 0.5 mM EDTA; 0.5 mM EGTA; 150 mM NaCl; 10% Glycerol; 50 mM NaF; 100 mM NaVO4; 40 mM beta-Glycerophosphate) was degassed with Argon for 20 min before adding 1% TritonX-100; 2 mM PMSF; 5 mg/ml Aprotinin; N-ethylmaleimide 40 mM; and bovine catalase 100 mug/ml. Plates were transferred into an anaerobic/argon cabinet and were washed twice with cold degassed PBS. Cells were then scraped into lysis buffer and lysed on ice for 20 min before conducting quantitative analysis as described above. A measure of 65 mug of protein were analysed under non-reducing conditions with a 7.5% SDS-PAGE.
###end p 42
###begin title 43
Co-immunoprecipitation
###end title 43
###begin p 44
###xml 4 6 4 6 <sup>WT</sup>
###xml 110 112 110 112 <sup>WT</sup>
###xml 122 130 122 130 <sup>C51/172S</sup>
###xml 137 141 137 141 <sup>C51S</sup>
###xml 148 153 148 153 <sup>C172S</sup>
PTENWT (Addgene) was subcloned into a pQCXI vector (Clonetech) and N-terminally tagged with Myc epitope. Prdx1WT and Prdx1C51/172S, Prdx1C51S, Prdx1C172S (generated by site-specific mutagenesis) were subcloned into a pCGN vector and N-terminally tagged with an HA epitope. All constructs were transfected into 293T/17 (ATCC) cells using Fugene transfection reagent (Roche). Cells were harvested 72 h later for protein lysis under anaerobic conditions (as described above). A measure of 1000 mug protein was immunoprecipitated using anti-HA affinity matrix overnight at 4degreesC before washing four times with degassed lysis buffer before analysis on 4-12% gradient SDS-PAGE. Proteins were detected as described above.
###end p 44
###begin title 45
GST-pull down
###end title 45
###begin p 46
###xml 304 305 303 304 <sub>2</sub>
###xml 308 309 307 308 <sub>4</sub>
###xml 320 321 319 320 <sub>2</sub>
###xml 323 324 322 323 <sub>4</sub>
###xml 1108 1109 1105 1106 <sub>2</sub>
BL21(DE3) were transformed and cultured overnight with pGEX-4T-2 (Amersham) ligated earlier with Prdx1. At absorbance of 0.6-0.8 at 600 nm, GST-Prdx1 expression was induced by the addition of IPTG (200 muM). Bacterial pellets were re-suspended using fusion protein buffer containing 140 mM NaCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, 2.7 mM KCl, 1 mM DTT, 50 muM PMSF, 5 mM benzamidine hydrochloride hydrate and 3 muM aprotinin. Lysate was then sonicated and proteins were solubilized by the addition of Triton X-100 (2%). After incubation of supernatant with glutathione affinity matrix, the matrix was washed consecutively with 500 mM NaCl, 50 mM NaCl and the GST-tagged fusion protein was eluted from the matrix by incubation with 30 mM reduced glutathione. The fusion protein was then desalted into 20 mM Tris (pH 7.4) and concentrated by centrifugation using a Centricon 30 kD MWC filter (Millipore, Bedford, MA). Incubations of equimolar concentrations (100 nM) of GST-Prdx1 plus His-PTEN or GST-EV (empty vector) plus His-PTEN were performed in a buffer containing 20 mM Hepes (pH 8.0), 150 mM NaCl, 2 mM MgCl2, 1 mM DTT, 50 muM PMSF, 5 mM benzamidine hydrochloride, 3 muM aprotinin and 1%Triton X-100. Mixtures were allowed to incubate overnight at 4degreesC before pre-washed glutathione agarose beads were added. The retained proteins were eluted from the resin by addition of 35 mul of 4 x loading buffer and analysed by 10% SDS gels.
###end p 46
###begin title 47
PTEN Plasmids
###end title 47
###begin p 48
###xml 112 114 112 114 <sup>WT</sup>
###xml 145 150 145 150 <sup>C124S</sup>
###xml 174 179 174 179 <sup>1&#8722;274</sup>
###xml 203 208 203 208 <sup>1&#8722;373</sup>
###xml 232 243 232 239 <sup>&#916;89&#8211;138</sup>
###xml 265 277 261 269 <sup>&#916;274&#8211;342</sup>
###xml 298 303 290 295 <italic>et al</italic>
###xml 288 309 280 301 <xref ref-type="bibr" rid="b30">Ramaswamy <italic>et al</italic>, 1999</xref>
###xml 332 336 324 328 <italic>BamH</italic>
###xml 338 342 330 334 <italic>EcoR</italic>
###xml 582 587 574 579 <sup>1&#8722;185</sup>
###xml 595 600 587 592 <sup>1&#8722;351</sup>
###xml 608 615 600 607 <sup>186&#8722;351</sup>
###xml 623 635 615 623 <sup>&#916;244&#8722;251</sup>
###xml 45 50 <span type="species:ncbi:9606">human</span>
Different lengths of cDNA fragments encoding human PTEN amino acids from 1-403 were subcloned from pSG5L HA-PTENWT (Addgene#10750), pSG5L-HA-PTENC124S (#10745), pSG5L-HA-PTEN1-274 (#10740), pSG5L-HA-PTEN1-373 (#10766), pSG5L-HA-PTENDelta89-138 (#10924), pGEX2T-PTENDelta274-342 (#10739) (Ramaswamy et al, 1999) at restriction sites BamHI/EcoRI. A double-stranded oligonucleotide encoding the Myc-tag sequence was inserted 5' of the PTEN to generate Myc-PTEN. Inserts tagged with Myc tag were cloned into pQCXIP to generate the corresponding pQCXIP-Myc-PTEN plasmids; pQCXIP-MYC-PTEN1-185 or PTEN1-351 or PTEN186-351 or PTENDelta244-251 were generated by PCR mutagenesis and confirmed by DNA sequencing. Prdx1 N- and C-terminal truncation mutants were generated by Bal31 nuclease digest, fill-in with T4-polymerase and subcloned into pCGN-HA.
###end p 48
###begin title 49
Recombinant Prdx1 activity assay
###end title 49
###begin p 50
###xml 133 138 133 138 <italic>et al</italic>
###xml 128 145 128 145 <xref ref-type="bibr" rid="b2">Chae <italic>et al</italic>, 1994b</xref>
###xml 202 203 202 203 <sub>2</sub>
###xml 204 205 204 205 <sub>2</sub>
###xml 252 255 246 249 <sub>340</sub>
###xml 358 359 352 353 <sub>2</sub>
###xml 360 361 354 355 <sub>2</sub>
###xml 905 906 896 897 <italic>R</italic>
###xml 906 907 897 898 <sup>2</sup>
Prdx1 peroxidase activity was studied by standard Trx/Trx reductase (TrxR)/NADPH-coupled spectrophotometric assay as described (Chae et al, 1994b). Briefly, NADPH oxidation coupled to the reduction of H2O2 was monitored at 37degreesC as a decrease in A340 using a SpectraMax M5 plate reading spectrophotometer. The reaction was initiated by addition of the H2O2 (500 muM) as a substrate into a reaction mixture containing 50 mM Hepes (pH 7.0), 0.15 U TrxR, 18 muM Trx, 25 muM NADPH and 680 nM Prdx1 (Sigma). The effect of PTEN on Prdx1 activity was studied by titration of reaction mixture with indicated increasing amount of PTEN (0.25-1.25 PTEN/Prdx1 mol/mol ratio). All experimental data were normalized to initial (before addition of substrate) absorbency and fitted with linear regression (Sigma Plot 10, Systat Software, Inc., San Jose, CA). Quality of fit was controlled by regression coefficient (R20.9).
###end p 50
###begin title 51
PTEN inositol phosphatase activity
###end title 51
###begin p 52
###xml 305 336 305 336 <xref ref-type="bibr" rid="b34">Schwartzbauer and Robbins, 2001</xref>
###xml 721 722 715 716 <sub>3</sub>
###xml 776 777 770 771 <sub>2</sub>
###xml 909 910 903 904 <sub>2</sub>
Myc-PTEN was expressed in 293T/17 cells in the presence or absence of HA-Prdx1. Cells were lysed as described above in phosphatase inhibitors free lysis buffer. PTEN proteins were immunoprecipitated from lysates with anti-PTEN (Santa Cruz) o/n as described above. IPs were then washed twice as described (Schwartzbauer and Robbins, 2001), followed by a final wash in PTEN enzyme reaction buffer (10 mM Hepes, 150 mM NaCl, 10 mM DTT pH 7.2). The phosphatase reactions were done following manufacturer's instructions (Echelon Biosciences). Briefly, the immunoprecipitated PTEN proteins were incubated with PTEN enzyme reaction buffer for an appropriate amount of time at 37degreesC in a 96-well plate coated with PI(3,4,5)P3. After removal of PTEN proteins from plates, PI(4,5)P2 was determined according to the manufacturer's instructions. Absorbance was measured at 450 nm in a microplate reader, and PI(4,5)P2 produced was calculated from a standard curve.
###end p 52
###begin title 53
Recombinant PTEN inositol phosphatase activity
###end title 53
###begin p 54
###xml 132 133 131 132 <sub>2</sub>
###xml 134 135 133 134 <sub>2</sub>
###xml 202 203 201 202 <sub>2</sub>
###xml 204 205 203 204 <sub>2</sub>
###xml 987 988 985 986 <sub>2</sub>
###xml 989 990 987 988 <sub>2</sub>
###xml 42 47 <span type="species:ncbi:9606">human</span>
###xml 557 562 <span type="species:ncbi:9606">human</span>
A measure of 20 pmol purified recombinant human His-PTEN was incubated with different amounts of Prdx1 (Sigma Aldrich) and 500 muM H2O2 in 20 mM Tris-Cl (pH 7.4) buffer at room temperature for 10 min. H2O2 was removed by Bio-Gel P-6 chromatography columns (Bio-Rad), following the manufacture's instructions. The protein mixture was then loaded onto PTEN activity assay plates as described above (Echelon Biosciences). Equal amount of PTEN was confirmed by western blot with the PTEN antibody. For Prdx1 peptide interference, 20 pmoles purified recombinant human His-PTEN was pre-incubated with 20-fold excess amount of peptides on ice in 20 mM Tris-Cl (pH 7.4) (for Peptide 1 or scramble peptide 1) or 0.2 mM Tris-Cl (pH 7.4) (peptide 2 or scramble peptide 2) for 1 h, the unbound peptides were removed by Microcon Ultracel YM-10 filters following the manufacture's instructions. The recovered PTEN-peptide mixtures were then incubated with 20 pmoles Prdx1 (Sigma Aldrich) and 500 muM H2O2 in 20 mM Tris-Cl (pH 7.4) buffer at room temperature for 10 min and further processed as described above. Peptide 1: MSSGNAKIGHPAPNFKATAVM; scrambled peptide 1: KTHPMPSIAAKFNAGSNAMVG; Peptide 2: PAGWKPGSDTIKPDVQKSKEYFSKQK; scrambled peptide 2: IKKSWKFGPGQPTSAPKQSKEVKYDD; all peptides had purity >75% and were purchased from Genscript, NJ.
###end p 54
###begin title 55
###xml 4 7 4 7 <sup>&#8722;/&#8722;</sup>
PTEN-/-MEFs experiments
###end title 55
###begin p 56
###xml 172 175 172 175 <italic>Age</italic>
###xml 177 181 177 181 <italic>EcoR</italic>
###xml 195 198 195 198 <sup>&#8722;/&#8722;</sup>
###xml 390 395 389 394 <italic>et al</italic>
###xml 383 401 382 400 <xref ref-type="bibr" rid="b18">Leslie <italic>et al</italic>, 2000</xref>
###xml 439 442 438 441 <italic>Age</italic>
###xml 444 448 443 447 <italic>EcoR</italic>
###xml 455 464 454 463 <sup>&#8722;/&#8722;;pMKO1</sup>
###xml 476 487 475 486 <sup>&#8722;/&#8722;;shPrdx1</sup>
###xml 637 640 635 638 <sup>V12</sup>
An optimal sequence for knock down of Prdx1 by sh (5'-GCTCAGGATTATGGAGTCTTA-3') was identified from the TRC consortium () and was subcloned into pMKO1 retroviral vector by AgeI/EcoRI digest. PTEN-/-MEFs were infected with retroviral supernatant containing either pMKO1-Prdx1shRNA or pMKO1 EV, and selected in puromycin 2 mug/ml for 1 week. GFP-PTEN was subcloned from pEGFP-C2-PTEN (Leslie et al, 2000) into pQCXIP at restriction sites of AgeI-EcoRI. PTEN-/-;pMKO1MEFs or PTEN-/-;shPrdx1MEFs were then transduced with GFP-PTEN retrovirus and selected in 6 mug/ml puromycin. Infection and selection with retrovirus expressing either H-RasV12 or ErbB-2/neuT was then challenged by 10 mug/ml puromycin.
###end p 56
###begin title 57
###xml 0 4 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 13 17 <span type="species:ncbi:10090">mice</span>
MMTV-v-H-Ras mice lacking Prdx1
###end title 57
###begin p 58
###xml 24 29 24 29 <italic>et al</italic>
###xml 19 35 19 35 <xref ref-type="bibr" rid="b36">Sinn <italic>et al</italic>, 1987</xref>
###xml 77 80 77 80 <sup>+/&#8722;</sup>
###xml 134 137 134 137 <sup>&#8722;/&#8722;</sup>
###xml 160 163 160 163 <sup>+/+</sup>
###xml 328 331 328 331 <sup>&#8722;/&#8722;</sup>
###xml 354 357 354 357 <sup>+/+</sup>
###xml 359 360 359 360 <italic>n</italic>
###xml 418 423 418 423 <italic>et al</italic>
###xml 409 429 409 429 <xref ref-type="bibr" rid="b6">Fujiwara <italic>et al</italic>, 2005</xref>
###xml 0 4 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 13 17 <span type="species:ncbi:10090">mice</span>
###xml 81 85 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 94 98 <span type="species:ncbi:10090">mice</span>
###xml 138 142 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 164 168 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 177 181 <span type="species:ncbi:10090">mice</span>
###xml 183 187 <span type="species:ncbi:10090">Mice</span>
###xml 239 244 <span type="species:ncbi:10090">Mouse</span>
###xml 310 314 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 336 340 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 364 368 <span type="species:ncbi:10090">mice</span>
MMTV-v-H-Ras mice (Sinn et al, 1987) were purchased from Charles River. Prdx1+/-/MMTV-v-H-Ras mice were intercrossed to generate Prdx1-/-/MMTV-v-H-Ras and Prdx1+/+/MMTV-v-H-Ras mice. Mice were monitored twice a week for tumour appearance. Mouse mammary glands were isolated from age-matched 16-week-old female MMTV-v-H-ras/Prdx1-/- and MMTV-v-H-ras/Prdx1+/+ (n=3) mice following earlier described procedures (Fujiwara et al, 2005). Proteins were processed as described above.
###end p 58
###begin title 59
Supplementary Material
###end title 59
###begin p 60
Supplementary Figures S1-S5
###end p 60
###begin p 61
###xml 363 366 363 366 <sup>&#8722;/&#8722;</sup>
###xml 322 326 <span type="species:ncbi:10090">mice</span>
We especially thank Drs Yusuf Hannun, Peter Sicinski, Alex Toker, Steve Rosenzweig and Scott Eblen for fruitful discussions. We thank Ningfei An and Joe Blumer for assistance with GST-pull down experiments and Joseph Moore for editorial assistance. We thank Dr Rick Van Etten for sharing the Prdx1-constructs and knockout mice and Vic Stambolic for providing PTEN-/-MEFs. We also thank Dr William Sellers for sharing the PTEN wild-type construct through Addgene. This work was supported by grants from the NIEHS-K22 ES012985, ACS-IRG-97-219-05, Claudia Adams Barr Award-DFCI. All (CAN), and Abney research Foundation-MUSC (JC) and (AK).
###end p 61
###begin article-title 62
###xml 46 51 <span type="species:ncbi:4932">yeast</span>
Thioredoxin-dependent peroxide reductase from yeast.
###end article-title 62
###begin article-title 63
Dimerization of a thiol specific antioxidant and the essential role of cystein 47.
###end article-title 63
###begin article-title 64
###xml 78 82 <span type="species:ncbi:10090">mice</span>
The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice.
###end article-title 64
###begin article-title 65
Membrane-binding and activation mechanism of PTEN.
###end article-title 65
###begin article-title 66
Regulation of reactive oxygen species, DNA damage, and c-Myc function by peroxiredoxin 1.
###end article-title 66
###begin article-title 67
Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells.
###end article-title 67
###begin article-title 68
SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling.
###end article-title 68
###begin article-title 69
###xml 19 34 <span type="species:ncbi:10633">simian virus 40</span>
###xml 71 76 <span type="species:ncbi:9606">human</span>
Enumeration of the simian virus 40 early region elements necessary for human cell transformation.
###end article-title 69
###begin article-title 70
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice deficient in cellular glutathione peroxidase develop normally and show no increased sensitivity to hyperoxia.
###end article-title 70
###begin article-title 71
Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion.
###end article-title 71
###begin article-title 72
The role of PTEN signaling perturbations in cancer and in targeted therapy.
###end article-title 72
###begin article-title 73
Prx1 suppresses radiation-induced c-Jun NH2-terminal kinase signaling in lung cancer cells through interaction with the glutathione S-transferase Pi/c-Jun NH2-terminal kinase complex.
###end article-title 73
###begin article-title 74
Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity.
###end article-title 74
###begin article-title 75
Reversible oxidation and inactivation of the tumor suppressor PTEN in cells stimulated with peptide growth factors.
###end article-title 75
###begin article-title 76
Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association.
###end article-title 76
###begin article-title 77
Reversible inactivation of the tumor suppressor PTEN by H2O2.
###end article-title 77
###begin article-title 78
Redox regulation of PI3-kinase signaling via inactivation of PTEN.
###end article-title 78
###begin article-title 79
Analysis of the cellular functions of PTEN using catalytic domain and C-terminal mutations: differential effects of C-terminal deletion on signalling pathways downstream of phosphoinositide 3-kinase.
###end article-title 79
###begin article-title 80
Transformation potential of Ras isoforms correlates with activation of phosphatidylinositol 3-kinase but not ERK.
###end article-title 80
###begin article-title 81
Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance.
###end article-title 81
###begin article-title 82
###xml 13 32 <span type="species:ncbi:210">Helicobacter pylori</span>
Structure of Helicobacter pylori catalase, with and without formic acid bound, at 1.6 A resolution.
###end article-title 82
###begin article-title 83
###xml 105 130 <span type="species:ncbi:11757">mouse mammary tumor virus</span>
###xml 132 136 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 152 156 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 174 189 <span type="species:ncbi:10090">transgenic mice</span>
Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice.
###end article-title 83
###begin article-title 84
###xml 55 58 <span type="species:ncbi:10116">rat</span>
Dimer-oligomer interconversion of wild-type and mutant rat 2-Cys peroxiredoxin: disulfide formation at dimer-dimer interfaces is not essential for decamerization.
###end article-title 84
###begin article-title 85
Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN's lipid phosphatase activity and membrane binding: a mechanism for the functional loss of PTEN's tumor suppressor activity.
###end article-title 85
###begin article-title 86
Are peroxiredoxins tumor suppressors?
###end article-title 86
###begin article-title 87
Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defense and tumor suppression.
###end article-title 87
###begin article-title 88
Role of the c-Abl tyrosine kinase in the cellular response to oxidative stress.
###end article-title 88
###begin article-title 89
A chemical proteomics approach to phosphatidylinositol 3-kinase signaling in macrophages.
###end article-title 89
###begin article-title 90
Electrostatic evaluation of the signature motif (H/V)CX5R(S/T) in protein-tyrosine phosphatases.
###end article-title 90
###begin article-title 91
Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway.
###end article-title 91
###begin article-title 92
Regulation of protein phosphatase 2A by hydrogen peroxide and glutathionylation.
###end article-title 92
###begin article-title 93
Cell signaling. H2O2, a necessary evil for cell signaling.
###end article-title 93
###begin article-title 94
###xml 56 61 <span type="species:ncbi:9606">human</span>
Crystal structure of decameric 2-Cys peroxiredoxin from human erythrocytes at 1.7 A resolution.
###end article-title 94
###begin article-title 95
The tumor suppressor gene PTEN can regulate cardiac hypertrophy and survival.
###end article-title 95
###begin article-title 96
Akt/PKB activity is required for Ha-Ras-mediated transformation of intestinal epithelial cells.
###end article-title 96
###begin article-title 97
###xml 102 109 102 109 <italic>in vivo</italic>
###xml 15 19 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 33 37 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 53 68 <span type="species:ncbi:10090">transgenic mice</span>
Coexpresson of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo.
###end article-title 97
###begin article-title 98
Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner.
###end article-title 98
###begin article-title 99
Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN.
###end article-title 99
###begin article-title 100
Inhibition of H-Ras transformation by the PTEN/MMAC1/TEP1 tumor suppressor gene.
###end article-title 100
###begin article-title 101
Tumor suppressor PTEN acts through dynamic interaction with the plasma membrane.
###end article-title 101
###begin article-title 102
###xml 49 54 <span type="species:ncbi:9606">human</span>
The phosphatidylinositol 3-kinase AKT pathway in human cancer.
###end article-title 102
###begin article-title 103
The Pag gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity.
###end article-title 103
###begin article-title 104
Reversible oxidation of the active site cysteine of peroxiredoxins to cysteine sulfinic acid. Immunoblot detection with antibodies specific for the hyperoxidized cysteine-containing sequence.
###end article-title 104
###begin article-title 105
###xml 16 21 <span type="species:ncbi:9606">human</span>
Inactivation of human peroxide 1 during catalysis as the result of the oxidation of the catalytic site to cysteine-sulfinic acid.
###end article-title 105
###begin article-title 106
Specific protection against breast cancers by cyclin D1 ablation.
###end article-title 106
###begin article-title 107
Active site labeling of the Yersinia protein tyrosine phosphatase: the determination of the pKa of the active site cysteine and the function of the conserved histidine 402.
###end article-title 107
###begin p 108
###xml 1 2 1 2 <bold>A</bold>
###xml 25 26 25 26 <sub>2</sub>
###xml 27 28 27 28 <sub>2</sub>
###xml 113 137 113 137 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure S1A</xref>
###xml 140 141 140 141 <sub>2</sub>
###xml 142 143 142 143 <sub>2</sub>
###xml 175 176 175 176 <sup>6</sup>
###xml 195 196 195 196 <italic>P</italic>
###xml 248 249 248 249 <italic>t</italic>
###xml 265 266 265 266 <sub>2</sub>
###xml 267 268 267 268 <sub>2</sub>
###xml 285 288 285 288 <sup>&#8722;/&#8722;</sup>
###xml 319 329 319 329 <sup>&#8722;/&#8722;Prdx1WT</sup>
###xml 335 336 335 336 <sup>*</sup>
###xml 336 337 336 337 <italic>P</italic>
###xml 352 370 352 370 <sup>&#8722;/&#8722;Prdx1Cys51/172S</sup>
###xml 372 374 372 374 <sup>**</sup>
###xml 374 375 374 375 <italic>P</italic>
###xml 684 685 684 685 <sub>2</sub>
###xml 688 689 688 689 <sub>3</sub>
###xml 696 701 696 701 <italic>et al</italic>
###xml 692 707 692 707 <xref ref-type="bibr" rid="b43">Woo <italic>et al</italic>, 2003</xref>
###xml 711 712 711 712 <bold>B</bold>
###xml 731 734 731 734 <sup>&#8722;/&#8722;</sup>
###xml 748 751 748 751 <sup>+/+</sup>
###xml 816 821 816 821 <italic>Prdx1</italic>
###xml 821 823 821 823 <sup>WT</sup>
###xml 827 832 827 832 <italic>Prdx1</italic>
###xml 832 840 832 840 <sup>C51/172S</sup>
###xml 908 911 908 911 <sup>V12</sup>
###xml 1146 1147 1146 1147 <bold>C</bold>
###xml 1158 1159 1158 1159 <sub>2</sub>
###xml 1160 1161 1160 1161 <sub>2</sub>
###xml 1455 1456 1455 1456 <italic>P</italic>
###xml 1508 1509 1508 1509 <italic>t</italic>
###xml 1516 1517 1516 1517 <sup>*</sup>
###xml 1517 1518 1517 1518 <italic>P</italic>
###xml 1526 1528 1526 1528 <sup>**</sup>
###xml 1528 1529 1528 1529 <italic>P</italic>
###xml 1557 1560 1557 1560 <sup>+/+</sup>
(A) Left panel: rate of H2O2 release per minute was analysed by calculating the linear slope of data obtained in Supplementary Figure S1A. H2O2 release is expressed per 1 x 106 cells per minute. P-values were calculated using an unpaired Student's t-test. Rate of H2O2 release in Prdx1-/-MEFs compared with either Prdx1-/-Prdx1WTMEFs (*P=0.04) or Prdx1-/-Prdx1Cys51/172S (**P=0.001). Right panel: protein levels and oxidation status of expressed Prdx1 in MEFs used in left panel. Protein lysates were prepared as described under Materials and methods and analysed under non-reducing conditions. Status of over-oxidized Prdx1 was tested by using an antibody recognizing Prdx1 (Prdx1-SO2/SO3) (Woo et al, 2003). (B) Left panel: Prdx1-/-MEFs and Prdx1+/+MEFs were infected with retroviral constructs carrying genes for Prdx1WT or Prdx1C51/172S. MEFs were further infected with retrovirus expressing either H-RasV12 or puromycin resistance gene only (EV) and plated in duplicates in soft agar. Colonies were counted after 18-20 days. Right panel: proteins of clones used in soft agar experiment were analysed for expression levels of Prdx1 and Ras. (C) Rate of H2O2 release per minute was analysed by calculating the linear slope of MEFs used in (B, left panel). For each clone, six wells were plated and analysed. The experiment shown here is representative of three independent studies from two different sets of MEF clones obtained from Prdx1 littermates. P-values were calculated using an unpaired Student's t-test. *P=0.045; **P=0.004. Differences in Prdx1+/+MEFs were not statistically significant.
###end p 108
###begin p 109
###xml 1 2 1 2 <bold>A</bold>
###xml 9 12 9 12 <sup>&#8722;/&#8722;</sup>
###xml 26 29 26 29 <sup>+/+</sup>
###xml 56 57 56 57 <sub>2</sub>
###xml 58 59 58 59 <sub>2</sub>
###xml 353 354 353 354 <bold>B</bold>
###xml 361 364 361 364 <sup>&#8722;/&#8722;</sup>
###xml 378 381 378 381 <sup>+/+</sup>
###xml 506 507 506 507 <bold>C</bold>
###xml 799 800 799 800 <italic>y</italic>
###xml 934 935 934 935 <bold>D</bold>
###xml 942 945 942 945 <sup>&#8722;/&#8722;</sup>
###xml 959 962 959 962 <sup>+/+</sup>
###xml 1076 1077 1076 1077 <bold>E</bold>
###xml 1084 1087 1084 1087 <sup>&#8722;/&#8722;</sup>
###xml 1101 1104 1101 1104 <sup>+/+</sup>
###xml 1229 1230 1229 1230 <bold>F</bold>
###xml 1416 1417 1416 1417 <bold>G</bold>
###xml 1460 1461 1460 1461 <sub>2</sub>
###xml 1462 1463 1462 1463 <sub>2</sub>
(A) Prdx1-/-MEFs and Prdx1+/+MEFs were stimulated with H2O2 as indicated. Protein lysates were collected under argonized conditions by scraping cells into argon-purged lysis buffer (see Materials and methods) and analysed under non-reducing conditions on SDS-PAGE. Akt phosphorylation was detected on Ser473 and Thr308. Akt protein as loading control. (B) Prdx1-/-MEFs and Prdx1+/+MEFs protein lysates were treated as described under (A) and analysed for oxidized PTEN proteins. Actin as loading control. (C) Levels of oxidized PTEN proteins were evaluated by quantifying oxidized and reduced PTEN using a Fuji imaging system (LAS 3000) and related software (ImageGuage). Quantifications of staining intensities were obtained by analysing protein bands from the same ECL obtained film exposure. The y-axis represents staining intensities in arbitrary units of oxidized PTEN. Curves represent data from three independent experiments. (D) Prdx1-/-MEFs and Prdx1+/+MEFs were stimulated with PDGF as indicated. Protein lysates were collected and analysed as described under (A). (E) Prdx1-/-MEFs and Prdx1+/+MEFs protein lysates were treated as described under (D) and analysed for oxidized PTEN proteins. Actin as loading control. (F) Data analysis was done as described under (C). All experiments shown are representative of at least three independent studies including two sets of MEF clones from Prdx1 littermates. (G) Serum starved MEFs were stimulated with H2O2 as indicated. Protein lysates were collected and analysed as described under (A). Akt substrates were detected by western blotting using an phospho-Akt substrate antibody (RXRXXS/T).
###end p 109
###begin p 110
###xml 1 2 1 2 <bold>A</bold>
###xml 456 457 455 456 <bold>B</bold>
###xml 593 594 592 593 <sub>2</sub>
###xml 595 596 594 595 <sub>2</sub>
###xml 884 885 883 884 <sub>2</sub>
###xml 889 890 888 889 <sub>3</sub>
###xml 1078 1079 1077 1078 <sub>2</sub>
###xml 1083 1084 1082 1083 <sub>3</sub>
###xml 1275 1305 1274 1304 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure S3A and B</xref>
###xml 1309 1310 1308 1309 <bold>C</bold>
###xml 1333 1341 1332 1340 <sup>C51/172S</sup>
###xml 1393 1394 1392 1393 <sub>2</sub>
###xml 1398 1399 1397 1398 <sub>3</sub>
###xml 1419 1427 1418 1426 <sup>C51/172S</sup>
###xml 1430 1431 1429 1430 <bold>D</bold>
###xml 1665 1666 1664 1665 <bold>E</bold>
###xml 1960 1961 1959 1960 <bold>F</bold>
###xml 2097 2098 2096 2097 <bold>G</bold>
###xml 2202 2224 2201 2223 <xref ref-type="bibr" rid="b7">Guex and Peitsch, 1997</xref>
###xml 2227 2228 2226 2227 <sup>*</sup>
(A) Epitope-tagged PTEN was expressed in 293T cells. Cell lysate was prepared under anaerobic conditions and immunoprecipitates were prepared as described in Materials and methods. A measure of 1000 mug of protein was immunoprecipitated (anti-PTEN antibody; Santa Cruz). Proteins were analysed by SDS-PAGE. PTEN and Prdx1 proteins were detected by staining membranes with anti-PTEN (138G6, Cell Signaling) and anti-Prdx1 (Abcam) antibodies, respectively. (B) Epitope-tagged PTEN and Prdx1 wild type were co-expressed in 293T cells. Before lysis, cells were treated with increasing dosages of H2O2 as indicated for 15 min. Cell lysates were prepared under anaerobic conditions, and precipitated over night using HA-conjugated agarose beads. IPs were washed four times with argon-purged lysis buffer and analysed by western blotting. Proteins were detected with anti-PTEN, anti-Prdx1-SO2/-SO3 and anti-Prdx1 antibodies. Epitope-tagged Prdx1 migrates slower electrophoretically than endogenous Prdx1, labelled as HA-Prdx1. Epitope-tagged PTEN is labelled as Myc-PTEN. Anti-Prdx1-SO2/-SO3 can cross-react with Prdx2-4 and stains more intense in the IP proteins due to over night incubation and longer exposure to atmospheric oxygen. In contrast, lysates were immediately frozen (Supplementary Figure S3A and B). (C) Myc-PTEN and HA-Prdx1C51/172S were analysed as described under (B). Anti-Prdx1-SO2/-SO3 does not bind Prdx1C51/172S. (D) Recombinant His-PTEN (100 nM) was applied to equimolar GST or GST-Prdx1 and incubated over night. Glutathione sepharose (GST) beads were added for GST-pull down and analysed by western blotting. Input represents 1/50 of the total. (E) HA-Prdx1 wild type and cysteine to serine mutants of catalytically active Prdx1 cysteines were co-expressed with Myc-tagged PTEN wild type. HA-IPs were processed as under (B). Left side shows co-immunoprecipitations, right side shows expression of PTEN and Prdx1 cysteine to serine mutants. (F) Schematic domain structure of potential interaction sites of Prdx1 with PTEN (upper schematic) and PTEN with Prdx (lower schematic). (G) Identification of potential interaction sites using computer modelling (SwissPdb Viewer version 4; ) (Guex and Peitsch, 1997). *Prdx1 N terminus.
###end p 110
###begin p 111
###xml 1 2 1 2 <bold>A</bold>
###xml 99 100 99 100 <sub>2</sub>
###xml 101 102 101 102 <sub>2</sub>
###xml 312 313 312 313 <sub>3</sub>
###xml 572 573 570 571 <bold>B</bold>
###xml 587 588 584 585 <sub>2</sub>
###xml 589 590 586 587 <sub>2</sub>
###xml 840 841 837 838 <bold>C</bold>
###xml 1259 1260 1254 1255 <bold>D</bold>
###xml 1519 1520 1513 1514 <sub>2</sub>
###xml 1521 1522 1515 1516 <sub>2</sub>
###xml 1715 1717 1709 1711 <sup>&#8722;1</sup>
###xml 1720 1722 1714 1716 <sup>&#8722;1</sup>
###xml 1819 1820 1813 1814 <bold>E</bold>
###xml 1944 1945 1938 1939 <italic>K</italic>
###xml 1947 1948 1941 1942 <italic>y</italic>
###xml 1951 1953 1945 1947 <italic>Kx</italic>
###xml 1961 1962 1955 1956 <italic>y</italic>
###xml 1995 1996 1989 1990 <italic>x</italic>
(A) Epitope-tagged Myc-PTEN and HA-Prdx1 were co-expressed in 293T cells, which were treated with H2O2 for 15 min, as indicated. Cell lysates were prepared under anaerobic conditions, and precipitated over night as described above by using anti-PTEN antibody. PTEN-immunoprecipitates were analysed for PI(3,4,5)P3-utilization in a 96-well plate assay as described in Materials and methods (triplicate samples). All results are presented as mean+/-s.e. (or difference) for at least two independent experiments. Equal PTEN protein amount was confirmed by western blotting. (B) 500 muM of H2O2 was added to either 20 pmoles of recombinant His-purified PTEN in the presence of different amounts of recombinant purified Prdx1 as indicated and described in Materials and methods. Experiment shown is representative of three independent studies. (C) PTEN activity was measured as described in (B) in the presence of peptides interfering with Prdx1 binding to PTEN. P1 (peptide 1) is replica of first N-terminal 21 amino acids (AS) of Prdx1; P1 Sc, scrambled sequence of P1; P2 (peptide 2), replica of last C-terminal 26 AS of Prdx1; P2 Sc, scrambled sequence of P2. The results are presented as mean+/-s.e. (or difference) for at least two independent experiments. (D) Prdx1 peroxidase activity was measured by a standard thioredoxin (Trx)/thioredoxin reductase (TrxR)/NADPH-coupled spectrophotometric assay (see Materials and methods for details). A measure of 20 pmoles of purified Prdx1 (Sigma) was incubated with 500 muM H2O2 and increasing molar amounts of purified His-PTEN as indicated. Prdx1 peroxidase activity (without PTEN) was about 68 nmol/mg protein/min under those conditions (extinction coefficient 6.62 mM-1 cm-1 for NADPH at 340 nm). Experiment shown is representative of three to four independent studies. (E) Relative reaction velocity of Prdx1 peroxidase activity from (D) was determined by plotting linear regression coefficient K (y=a-Kx, where y is the absorbency at 340 nm and x is time) versus various PTEN/Prdx1 (mol/mol) ratios. The results are presented as mean+/-s.e. (or difference) for at least two independent experiments.
###end p 111
###begin p 112
###xml 1 2 1 2 <bold>A</bold>
###xml 8 11 8 11 <sup>&#8722;/&#8722;</sup>
###xml 62 63 62 63 <sub>2</sub>
###xml 64 65 64 65 <sub>2</sub>
###xml 129 135 129 135 <sup>Ser473</sup>
###xml 158 159 158 159 <bold>B</bold>
###xml 165 168 165 168 <sup>&#8722;/&#8722;</sup>
###xml 319 320 318 319 <sub>2</sub>
###xml 321 322 320 321 <sub>2</sub>
###xml 418 419 417 418 <sup>*</sup>
###xml 467 468 466 467 <bold>C</bold>
###xml 474 477 473 476 <sup>&#8722;/&#8722;</sup>
###xml 547 550 546 549 <sup>V12</sup>
###xml 684 685 683 684 <sup>*</sup>
###xml 685 686 684 685 <italic>P</italic>
###xml 704 705 703 704 <italic>t</italic>
###xml 714 715 713 714 <bold>D</bold>
###xml 777 780 776 779 <sup>V12</sup>
###xml 782 784 781 783 <sup>**</sup>
###xml 784 785 783 784 <italic>P</italic>
###xml 803 804 802 803 <italic>t</italic>
###xml 813 814 812 813 <bold>E</bold>
(A) PTEN-/-MEFs were serum starved for 48 h and treated with H2O2 as indicated for 10 min. Protein lysates were analysed for pAktSer473 as described before. (B) PTEN-/-MEFs were infected with retrovirus expressing GFP-PTEN. After 5-day selection in puromycin (2 mug/ml), MEFs were serum starved, exposed for 10 min to H2O2 and analysed for Prdx1 oxidation and formation of dimeric structures by non-reducing SDS-PAGE. *Prdx1 hetero-dimer formation with other Prdxs. (C) PTEN-/-MEFs were infected with retrovirus expressing shPrdx1, GFP-PTEN, H-RasV12 or various vectors carrying resistance gene only (pBabe, pMKO1). MEFs were plated in soft agar. Colonies were counted after 21 days. *P<0.001 (Student's t-test). (D) As under C, except MEFs express ErbB-2/neuT instead of H-rasV12. **P<0.039 (Student's t-test). (E) Immunoblotting of MEFs from (C and D).
###end p 112
###begin p 113
###xml 1 2 1 2 <bold>A</bold>
###xml 142 147 142 147 <italic>Prdx1</italic>
###xml 155 156 155 156 <bold>B</bold>
###xml 164 165 164 165 <italic>n</italic>
###xml 211 214 211 214 <sup>&#8722;/&#8722;</sup>
###xml 211 214 211 214 <bold><sup>&#8722;/&#8722;</sup></bold>
###xml 241 244 241 244 <sup>+/+</sup>
###xml 241 244 241 244 <bold><sup>+/+</sup></bold>
###xml 383 384 381 382 <sup>2</sup>
###xml 392 393 390 391 <bold>C</bold>
###xml 494 495 492 493 <sup>*</sup>
###xml 22 26 <span type="species:ncbi:10090">mice</span>
###xml 77 81 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 90 94 <span type="species:ncbi:10090">mice</span>
###xml 188 192 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 201 205 <span type="species:ncbi:10090">mice</span>
###xml 218 222 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 231 235 <span type="species:ncbi:10090">mice</span>
(A) The percentage of mice free of H-Ras-induced mammary tumours is shown in MMTV-v-H-Ras mice carrying only one, none, or both copies of the Prdx1 gene. (B) MECs (n=3) were isolated from MMTV-v-H-Ras mice/Prdx1-/- or MMTV-v-H-Ras mice/Prdx1+/+ and analysed on a non-reducing SDS-PAGE for PTEN oxidation as described above. Statistical analysis of PTEN oxidation was done using a chi2 test. (C) The same protein lysates were also analysed for Akt phosphorylation on Ser473, as described above. *Non-statistically significant.
###end p 113
###begin p 114
###xml 5 8 5 8 <sup>&#8722;/&#8722;</sup>
###xml 5 8 5 8 <bold><sup>&#8722;/&#8722;</sup></bold>
Prdx1-/-MEFs have a higher sensitivity to PI3K inhibitors in H-Ras or ErbB-2 induced transformation
###end p 114

